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Head and neck squamous cell carcinoma (HNSCC) refers to a group of 
biologically similar cancers which start in the upper aerodigestive tract, that 90% 
of them are squamous cell carcinomas originating from the mucosal lining of 
these regions. Platinum compounds such as cisplatin and carboplatin are 
frequently used as t he first-line chemotherapy for the treatment of the HNSCC. 
However, the therapeutic efficacies of these agents are often quite limited due to 
poor prognosis and development of resistance; moreover, high doses of 
platinating agents which are required for significant anti-tumor effect frequently 
lead to severe side effects that compromise the quality of life of the patients. 
Hence, novel pharmacological agents that are safe and can overcome 
chemoresistance are urgently required. Natural products offer rich and powerful 
sources of therapeutic leads for the drug development that could provide effective 
alternative strategies. Garcinol, a poly-isoprenylated benzophenone, is one of the 
major active compounds extracted from the dried rind of the fruit of Garcinia 
indica tree that has been reported to exhibit significant anti-neoplastic and 
chemopreventive roles in various tumor cell lines and in vivo tumor models in 
increasing number of studies in recent years. However, the molecular 
mechanism(s) through which garcinol elicits its anti-tumor activity, specifically in 
HNSCC, is unknown till date. Thus, in the present study, we investigated the 
potential effects of garcinol on human HNSCC, and analyzed whether garcinol 
could sensitize HNSCC to cisplatin in vitro and in a xenograft mouse model. 
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Firstly, we found that garcinol could exhibit diverse anti-cancer effects as 
it inhibited the proliferation of HNSCC cell lines, induced apoptosis, and 
abrogated HNSCC cell migration and invasion. When tested together with the 
conventional chemotherapeutic agent, garcinol could enhance the cytotoxic and 
apoptotic effects of cisplatin in a synergistic manner in HNSCC cells. We 
observed that garcinol suppressed the activation of various upstream kinases of 
STAT3 signaling cascade, thereby inhibited the constitutive and IL-6-induced 
STAT3 phosphorylation, nuclear translocation and DNA binding activity. 
Garcinol also exhibited an inhibitory effect on constitutive NF-κB activation, 
mediated through the suppression of TAK1 and IKK activation in HNSCC cells. 
We further noticed that the chemotherapeutic drug cisplatin was able to induce 
NF-κB activation, this cisplatin-induced NF-κB activation could also be 
significantly abrogated upon ga rcinol treatment. Furthermore, garcinol down-
modulated the expression of various STAT3 and NF-κB-regulated oncogenic 
gene products critical for HNSCC cell growth, survival, angiogenesis, metastasis 
and chemoresistance. Finally, whether garcinol can sensitize the HNSCC to 
cisplatin treatment was investigated in HNSCC xenograft mouse model. Our in 
vivo study showed that administration of garcinol alone significantly suppressed 
the growth of human HNSCC xenograft tumors in athymic nu/nu mice, and the 
combination treatment of garcinol and cisplatin exhibited greater anti-tumor effect. 
Analysis of tumor tissues further verified the inhibitory effects of garcinol on 
STAT3 and p65 activation in tumor samples from garcinol treated mice, and this 
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is correlated with the suppression of various markers of proliferation, survival, 
angiogenesis and invasion. 
Taken together, the present findings clearly demonstrate that anti-cancer 
activities of garcinol in human HNSCC cell lines and in xenograft mouse model, 
are mediated through the modulation of multiple pro-inflammatory signaling 
cascades, and thereby highlight the great potential of garcinol as an effective anti-





















Cancer, known clinically as a malignant neoplasm, is a group of diseases 
caused by uncontrolled growth of cells (1). Cancer is a major public health 
problem worldwide, with 12.7 million cases and causes 7.6 million cancer deaths 
estimated by the International Agency for Research on Cancer (IARC) in 2008 (2). 
The burden of cancer is projected to rise continuously due to global population 
growth and aging, and increasingly adoption of cancer-causing lifestyle (3). In the 
Singapore Cancer Registry Interim Annual Registry Report, it is reported cancer 
incidents have increased year on year from the year of 2008 to 2012 in Singapore. 
A total of 56,316 cases were diagnosed during this period. 
Normal cells evolve progressively to neoplastic state through the 
assemblage of genetic mutations and epigenetic alterations that confer them a 
selective survival advantage (4). Hanahan and Weinberg have described the key 
hallmark capabilities acquired by the cancer cells during the multistep process of 
human tumor pathogenesis. The first proposed six hall marks of cancer include 
self-sufficiency in growth signals, insensitivity to antigrowth signals, evading 
apoptosis, limitless replicative potential, sustained angiogenesis, and tissue 
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invasion and metastasis (5). Recently, enabling characteristics (genomic 
instability and mutation, and tumor promoting inflammation) and emerging 
hallmarks (reprogramming energy metabolism, and evading immune destruction) 
have been added to the list (4). In addition, the interactions between the cancer 
cells and tumor microenvironment contribute to the entire process of cancer 
etiology, progression and metastasis (6).  
 
1.2 Head and Neck Squamous Cell Carcinoma (HNSCC) 
Head and neck cancer is a complex disease which comprises a broad range 
of biologically similar epithelial malignancies start in the upper aerodigestive tract, 
including the lip, nasal cavity, oral cavity, paranasal sinuses, pharynx, and larynx 
(7, 8), and accounts for approximately 650,000 new cases and 350,000 c ancer-
related deaths worldwide annually (6.0% of cases and 5.2% deaths) (9). Almost 
all of the head and neck cancers are squamous cell carcinomas originating from 





Use of tobacco, alcohol consumption, and human papillomavirus (HPV) 
infection are the major risk factors for head and neck cancer, with tobacco and 
alcohol having interactive and synergistic effects (11, 12). Subsets of HNSCC, 
especially oropharyngeal cancer are identified to be attributed to high-risk type 
HPV infection (13, 14). The distributions of HNSCC subtypes are variant, for 
instance, the cancers of the lip and oral cavity is mostly found in Melanesia and 
southcentral Asia, while nasopharyngeal cancer is more prevalent in southeast 
Asia region (3), such variations are strongly associated to the relative distributions 
of major risk factors (15). According to the Singapore Cancer Registry Interim 
Annual Registry Report, nasopharyeal cancer ranks as t he eighth most frequent 
cancers in males in Singapore at the year of 2008-2012 (16). As one of the 
commonest cancers in Singapore, more than 800 new cases of HNSCC are 
diagnosed per year (17). 
 
1.2.2 Diagnosis and staging  
Early recognition of signs and symptoms is important for prompt diagnosis; 
however the symptoms of early stage HNSCC are usually vague. The 
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signs/symptoms vary with the anatomic location of primary tumor and the stage 
of the cancer (7). For example, common symptoms for early nasopharyngeal 
cancer include nasal obstruction, epistaxis, and serous otitis media, and patients 
with advanced tumor present with cranial neuropathies and posterior cervical 
lymphadenopathy (7). Whereas, cancers of the oropharynx, hypopharynx, and 
supraglottic larynx only produce symptoms such as persistent unilateral sore 
throat and otalgia in later stages (7). As a biofluid in close contact with HNSCC 
lesion, saliva has been studied for developing biomarkers to detect early cancers 
and minimal residual disease in a non-invasive manner (18). Several strategies 
have been designed to identify biomarkers such as HPV status, promoter 
hypermethylation profiles, telomerase activity, and differential gene expression 
profiles (18). Indeed, aberrant promoter methylation patterns of cancer-related 
genes in saliva and serum from HNSCC patients have been found to match the 
methylation profiles of primary tumors (19, 20). All these efforts have revealed 
the feasibility of saliva-based strategies for the early diagnosis of HNSCC. 
Accurate staging depends on multidisciplinary consultations usually involve 
complete head and neck examination (mirror and fiberoptic examination) coupled 
with other appropriate studies (biopsy, chest imaging, computed tomography (CT) 
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and/or magnetic resonance imaging (MRI) scan, tumor HPV test for 
oropharyngeal cancer and PET-CT for stage III/IV disease) as required (21). The 
TNM (primary tumor (T), regional lymph node (N) and involvement distant meta-
stasis (M)) staging system developed by the American Joint Committee on Cancer 
(AJCC) is widely used; it integrates all clinically available information and guides 
the therapeutic decision making (22). 
 
1.2.3 Field cancerization 
The term “field cancerization” was first proposed by Slaughter to describe 
the occurrence of many precancerous and cancerous lesions at multi-focal "field" 
along the upper aerodigestive tract owing to the prolonged exposure to 
environmental carcinogens such as tobacco and alcohol, as well as infection with 
high-risk oncogenic HPV types (8, 23, 24). There are frequent observations of 
abnormal tissues surrounding the tumors, and high rate of lateral occurrence of 
local recurrences and second primary tumors. The recent advances of techniques 
in molecular and genetic analysis revealed that the areas of histopathological 
abnormality surrounding malignant lesions and the primary tumor share genetic 
alterations as a indication of common clonal origin (25, 26). Different genetic 
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alterations take place in the subsequent development of various subclones, results 
in a variety of histopathologically diverse regions in a local anatomical area (27, 
28).  
 
1.2.4 Multistep carcinogenesis in HNSCC 
The multistep progression of HNSCC from premalignant lesion to 
invasive cancer type is characterized by the accumulation of genetic and 
epigenetic alterations associated with the morphological changes in the squamous 
epithelium (27-29). HNSCC is initiated and grows by t he process of clonal 
evolution driven by multiple mutations in the mucosa cells and subsequently 
progress to cytologically recognizable premalignant foci of dysplasia, and 
eventually to carcinoma in situ (CIS) or cancer (27, 29). Benign squamous 
hyperplasia which usually appears similar to normal mucosa already harbors early 
genetic changes, often with loss of heterozygocity (LOH) at chromosomal loci 9p 
and inactivation of p16. Further loss of chromosomes 3p and 17p along with the 
p53 mutation occurs in dysplasia, reflecting early tumorigenesis; whereas 
additional losses on 4q, 8p and 11q are typically present in carcinoma in situ or 
invasive squamous cell carcinomas (27, 28). 
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1.2.5 Genetic and epigenetic alterations in HNSCC 
1.2.5.1 p16INK4A-cyclin D1-CDK- Retinoblastoma (RB) axis  
The tumor suppressor gene p16INK4A is the dominantly disrupted 
component of RB pathway frequently encountered in HNSCC. The inhibitor of 
cyclin-dependent kinases (CDK) 4 and 6, p16 is commonly inactivated by gene 
mutation, homozygous deletion, and promoter hypermethylation in the early 
progression of HNSCC (30-32). Indeed, chromosomal loss at 9p21 where 
p16INK4A resides occurs in up to 80% of HNSCC patients. The loss of functional 
p16 confers the cancer cell the ability to escape from the replicative stress-
induced senescence (33). Overexpression of cyclin D1 and amplification of 11q13 
(where CCND1 is located), are found frequently in HNSCC and is usually 
associated with more aggressive disease (34-36). Rb mutations are rare in 
HNSCC, but loss of Rb have been observed in oral cancer with lower frequency 
(37-39), suggesting that further alterations in p16-Rb pathway would provide 
limited growth advantage in the presence of p16 inactivation, or Rb function 




1.2.5.2 TP53  
Inactivation of functional tumor suppressor TP53 is one of the most 
frequent genetic alterations in the early progression of HNSCC. Somatic mutation 
of TP53 and loss of heterozygocity of 17p13 where the TP53 gene resides is 
presented in more than 50% of the HNSCC (41-43). In HPV-positive tumors, loss 
of TP53 function is mediated by t he destruction of p53 protein induced by E6 
viral oncoprotein (44). Abrogation of p53 may lead to the increase of unchecked 
genetic alterations due to the absence of proper cellular response to DNA damage 
which may result in further tumor progression (45).  
 
1.2.5.3 EGFR pathway 
Epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a 
member of ErbB/HER family receptor tyrosine kinase that mediates the cellular 
effects in response to binding of ligands (46). EGFR can be activated by several 
natural ligands, including epidermal growth factor (EGF), transforming growth 
factor alpha (TGF-α), amphiregulin, epiregulin, betacellulin, and heparin-binding 
EGF-like growth factor (HB-EGF) (47). Upon ligand binding on the extracellular 
domain, EGFRs form homo- or hetero-dimers and stimulate the intrinsic 
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intracellular tyrosine kinase activities which transduce signals to regulate 
comprehensive signaling cascades involved in a wide range of cellular activities 
such as gene expression, cellular proliferation, differentiation and cell migration 
(46, 48). EGFRs are expressed differentially in tissues of epithelial, mesenchymal 
and neuronal origin, where they are required for various biological/developmental 
processes; it is critical in modulating specific aspects of vertebrate embryogenesis, 
and important in mammary gland development by promoting ductal growth (49, 
50).  
Soon after its discovery in 1978, EGFR was linked directly to human 
tumors (51). The deregulation of EGFR pathway can be achieved through 
different mechanisms in multiple cancers, such as gene mutation, overexpression 
or amplification of a component of the pathway. Overexpression of EGFR ligands, 
in particular TGF-α and EGF, would stimulate the EGFR cascade through 
autocrine or paracrine loop, which are often associated with poor survival and 
prognosis in broad range of cancers such as lung, colon, prostate and pancreatic 
carcinomas (47, 52, 53). Overexpression of EGFR by gene amplification or 
increased translation has been reported in diverse tumors like carcinomas of lung, 
breast and glioma usually coupled with the elevated level of its cognate ligands 
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(54, 55). Genetic mutations of EGFR have been identified by several studies, with 
epidermal growth factor receptor variant III (EGFRvIII) being the most prevalent 
one found in brain tumor, which result in the constitutive activation of the 
receptor (56). Carcinomas of the lung, breast and ovary have been shown to 
express the EGFRvIII variant, which implies broader implications to human 
cancers (57). Studies have demonstrated that over-expression of normal EGFR is 
able to induce cellular transformation in the presence of appropriate levels 
of ligands, and co-expression of EGFR and other ErbB family receptors is 
necessary to induce full transformation in vitro and in vivo (58).  
EGFR plays a very importance role in the pathogenesis of HNSCC. More 
than 90% of the HNSCC express increased level of EGFR mRNA and 
overexpression of EGFR protein has been observed in almost 50% of the head 
and neck tumors (59, 60), and EGFR overexpression in HNSCC has been 
associated with poor survival rates, decreased radiation sensitivity and higher risk 
of tumor recurrence (55, 61, 62). Autocrine and paracrine stimulation of EGFR by 
the ligands and mutational activation of EGFR gene have been also revealed as 
important mechanisms involved in the deregulation of EGFR in subsets of 
HNSCC (63, 64). EGFR acts as a central signal transducer of multiple important 
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signaling pathways including Ras-Raf-mitogen activated protein kinase (MAPK) 
cascade, phosphatidylinositol-3-kinase (PI3K)-phosphatase and tensin homolog 
(PTEN)-AKT axis, signal transducers and activators of transcription (STAT) 
pathway and phospholipase Cγ signaling which contribute to tumor growth, 
survival, angiogenesis, invasion and metastasis (65). 
 
1.2.5.4 STAT3 signaling cascade in HNSCC 
A network of cytokine and growth factors is essential in regulating the 
distinct biological processes of embryogenesis, immunity, inflammation, and 
hematopoiesis, many of which rely on the STAT pathway (66). The STAT family 
of transcription factors was first uncovered in the study of interferon (IFN) 
signaling by James E. Darnell (67). Seven STATs family members have been 
identified up to now, namely STAT 1, 2, 3, 4,  5a, 5b, and 6, which mediate the 
transcription of variety of genes involved in the development, immune response 
and growth control (68). STAT3 was first described as transcription factor that 
selectively binds to an enhancer element in the promoter region of acute-phase 
genes in interleukin-6 (IL-6) stimulated hepatocytes (69). Subsequently, it has 
been found that STAT3 signaling can be activated in response to various 
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cytokines and growth factors (70, 71). Compared to the other members of the 
family, STAT3 plays more diverse roles in the various biological activities; for 
example, STAT3 is involved in acute phase response, macrophage and B cell 
differentiation, migration of leukocyte, epidermal cell, and keratinocyte, and 
maintenance of the pluripotent state of proliferating embryonic stem cells (72, 73).  
In the 1990s, the link of STAT3 signaling and oncogenesis was established 
with the findings that STAT3 is constitutively phosphorylated STAT3 in the v-Src 
transformed cells and such activation is essential for the Src-mediated 
oncogenesis (74, 75). Moreover, expression of constitutively activated STAT3 in 
fibroblast is sufficient to mediate cellular transformation, and the transformed 
cells can form tumor in nude mice (76). Abnormal elevated levels of STAT3 has 
been detected at high frequency in numerous human malignancies, including 
leukemia’s, lymphomas, multiple myeloma, as w ell as so lid tumors like breast 
cancer, prostate cancer, renal cell carcinoma and HNSCC (77). The importance of 
STAT3 in oncogenesis has been further evidenced by the studies demonstrating 
cell growth inhibition and apoptosis using STAT3 dominant negative construct 
(78, 79). Furthermore, STAT3 has been found to contribute to different stages of 
carcinogenesis. STAT3 signaling supports tumor cell survival and proliferation by 
13 
 
upregulating anti-apoptotic factor B-cell lymphoma-extra large (Bcl-xL), survivin, 
cyclin D1 and c-Myc (71). Recently, STAT3 has been shown as the direct 
transcriptional activator of pro-angiogenic factors such as vascular endothelial 
growth factor (VEGF), hypoxia-inducible factor 1 (HIF1) and matrix 
metalloproteinases (MMPs) (80, 81). STAT3 also plays important roles in tumor 
inflammation and immunity by promoting pro-oncogenic inflammatory cascades, 
and by opposing anti-tumor immune responses (70). 
Several lines of evidence(s) have indicated that the constitutive activation 
of STAT3 is an early event in head and neck carcinogenesis (82-84), with tumors 
and adjacent mucosa from HNSCC patients exhibiting elevated STAT3 level, 
increased tyrosine phosphorylation and DNA binding activity compared to 
healthy individuals (82). Activation of STAT3 by phos phorylation in tumor is 
also linked to lower survival rates of HNSCC patients, thereby supporting a 
prognostic role of activated STAT3 (85, 86). Studies using antisense treatment 
and transfection of dominant-negative STAT3 constructs resulted in cell growth 
inhibition and apoptosis in HNSCC, provided promising evidence that 
constitutive STAT3 activation plays an essential role in HNSCC (82, 87). Several 
genes such as Bcl-xL, Mcl-1, and survivin which are regulated by STAT3 may 
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confer the survival advantage to tumors; among them, Bcl-xL is important in 
HNSCC as d ecreased expression level of Bcl-xL is observed in HNSCC 
xenografts treated with STAT3 antisense gene therapy (82). Furthermore, 
HNSCC cells transfected with dominant-active STAT3 mutant construct 
demonstrated increased proliferation both in vitro and in vivo, indicating that 
STAT3 activation can lead to HNSCC growth independent of growth factor 
stimulation (84). Given the pivotal role of activated STAT3 signaling cascade in 
the growth, proliferation and survival of HNSCC, molecular agents targeting 
STAT3 and the STAT3 signaling pathway such as duplex oligonucleotide of 
STAT3 (STAT3 decoy), phosphotyrosyl peptides, related peptidomimetics and 
small molecule compounds have been developed and found to inhibit growth of 
HNSCC cells both in vitro and in vivo (87-90). 
 
1.2.5.5 NF-κB signaling cascade in HNSCC  
Nuclear factor kappa B (NF-κB) was first identified as a DNA binding 
protein that specifically bound to the immunoglobulin κ light chain enhancer 
which is restricted in B cells by David Baltimore in 1986 (91). NF-κB is a Rel 
family transcription factor which consists of five members in mammalian cells, 
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namely, RelA (p65), and RelB, Rel (c-Rel), NF-κB1 (p50/p105) and NF-κB2 
(p52/p100) (92). Both classical and alternate pathways can activate the NF-κB 
signaling through IκB kinase (IKK) dependent manner. In the canonical pathway, 
the activated β subunit of IKK (IKKβ) phosphorylates the negative regulator of 
NF-κB, inhibitor of kappa B-α (IκBα) protein upon the activation of IKK complex, 
thereafter leads to the ubiquitination and proteasome-mediated degradation of 
IκBα. This releases the p65/p50 heterodimer and allows the translocation of NF-
κB complex to nucleus (93). Activation of non-canonical pathway involves the 
NF-κB-inducing kinase (NIK) mediated activation of IKKα homodimer which 
then activates p100/RelB by proteasomal degradation of its inhibitory C-terminal 
half for processing into p52/RelB heterodimer (94). Various pro-inflammatory 
cytokines, tumor necrosis factor (TNF), lipopolysaccharide (LPS) and other 
stimuli like DNA-damaging agents and viral proteins, working through the TNF 
receptor (TNFR), Toll-like receptor/ interleukin-1 (TLR/IL-1R) and T-cell 
receptor (TCR) activate the classical NF-κB pathway (93). Following the ligand 
receptor binding, signaling proceeds through TNFR-associated factor/receptor-
interacting protein (TRAF/RIP) complexes, usually with the engagement of TGF 
beta activated kinase 1 (TAK1), leading to canonical signaling (95). On the other 
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hand, the alternative pathway is stimulated by a more restricted set of cytokines 
that belong to the TNF superfamily, such as B-cell activating factor (BAFF), LTβ 
and CD40 (96). It is well established that the canonical NF-κB pathway is 
essential for inflammation and innate immunity, while non-canonical pathway 
plays a central role in the lymphoid organ development and adaptive immunity 
(97). In general, NF-κB family proteins are evolutionarily conserved mediators 
which integrate multiple stress stimuli to regulate innate and adaptive immune 
responses; they act broadly to influence gene expression events that impact cell 
survival, differentiation, proliferation, adhesion, immunity and inflammation (98, 
99). 
Aberrant NF-κB activation has been implied in the pathogenesis of various 
human diseases such as inflammatory diseases, metabolic disorders, and cancers 
which are related to inflammation, oxidative stress and enhanced cell proliferation 
(100, 101). The first evidence implicating the oncogenic potential of NF-κB was 
the identification of retroviral oncoprotein v-Rel which shares a R el 
transactivation domain with the mammalian homologues (102, 103). Numerous 
evidences have shown that constitutive activation of NF-κB is prevalent in most 
major human cancers mainly due to the aberrant activation of upstream signaling 
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molecules, or through the autocrine or paracrine activation by cytokines and 
growth factors, and sometimes by the genetic alteration of genes encoding NF-κB 
and IκB proteins (104, 105). The involvement of NF-κB has been reported in 
different stages of cancer development and progression. Recent studies using 
genetic mouse models have provided direct evidences that the IKKβ-dependent 
NF-κB activation is essential for initiation and promotion of inflammation-
associated cancer (106, 107). NF-κB stimulates the growth of malignant cells by 
activating pro-inflammatory genes such as granulocyte–macrophage colony-
stimulating factor (GM-CSF), IL-6 and TNF as well as cell cycle regulators cyclin 
D1, CDK2, and c-Myc (108, 109). NF-κB also inhibits programmed cell death by 
inducing target genes including Bcl-2 family members, cellular inhibitors of 
apoptosis (cIAPs) and caspase-8/FADD (FAS-associated death domain)-like IL-
1β-converting enzyme (FLICE) inhibitory protein (c-FLIP) (110). NF-κB 
promotes angiogenesis which facilitate the vascularization of tumors via directly 
or indirectly mediating angiogenic factor VEGF and chemokine such as IL-8 and 
monocyte chemoattractant protein-1 (MCP-1) (111, 112). The expression of 
various adhesion molecules including intercellular adhesion molecule 1 (ICAM-1), 
ELAM-1, and VCAM-1,and several matrix metalloproteinases such as MMP2 
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and MMP9 have been found to be regulated by NF-κB, that implicated the 
mediating role of NF-κB in the processes of epithelial-mesenchymal transition 
(EMT) and metastasis (113, 114). Accumulating evidence(s) over the last few 
years indicate that most chemotherapeutic agents and radiation therapy induce the 
activation of NF-κB and its mediator genes in different type of cancers which 
leads to the chemo- or radio-resistance in tumor cells, and inhibition of NF-κB 
increases sensitivity of cancer cells to the apoptotic action of chemotherapy and to 
radiation exposure (115). 
Many studies have documented the prevalence of constitutive activated 
NF-κB in HNSCC cell lines and tumor tissues specimens. For example, 
carcinogens in tobacco, autocrine or paracrine secretion of IL-1α, EGF and TGF-
α, as well as chronic HPV infection which are linked to tumorigenesis induce NF-
κB activation in HNSCC cell lines (116-120). The dysregulated NF-κB signaling 
modulates the expression of programs of functional genes that contributes to cell 
proliferation (cyclin D1), cell survival and therapeutic resistance (IL-6, cIAP1, 
Bcl-xL, YAP1), angiogenesis (VEGF, IL-8), immune and pro-inflammatory 
responses (cytokines, chemokines, cyclooxygenase-2 (COX-2) and invasion and 
metastasis (MMP9, ICAM-1) of HNSCC (121-125). Global gene profiling 
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analysis has demonstrated that NF-κB signaling significantly contributes to 
metastatic progression of HNSCC (126), and identified the activation of NF-κB as 
a major biomarker for high-risk HNSCC patients (127). Elevated phosphorylation 
level of NF-κB in patient samples is associated with poor prognosis in terms of 
high recurrence and poor survival (128). Different experiments have been 
designed to block the deregulated NF-κB activation to study the important role of 
NF-κB in HNSCC development and progression; such strategies include the 
overexpression of dominant-negative mutant of IκBα (IκBαM) which does not 
respond to IKK phosphorylation (129), expression of IKKα and IKKβ kinase dead 
mutants (130), and using pharmacological inhibitor bortezomib (131). The 
inhibition of NF-κB activation in HNSCC significantly suppresses the expression 
of NF-κB-modulated genes, such as pro-inflammatory cytokines (IL-6 and IL-8), 
and results in the induction of cell death and tumor growth inhibition (124, 132).  
 
1.2.6 Treatment options  
Current treatments of HNSCC are complicated, depending on the primary 
tumor sites, stages of the disease, and considerations for organ preservation, thus 
multidisciplinary approaches involving surgical excision, radiation therapy, and 
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chemotherapy are applied (133). Approximately one-third of the HNSCC patients 
present with highly confined stage I o r II d isease without regional metastases, 
while the other two-thirds of all patients present with advanced stage III or IV 
tumors with low locoregional control rates and 5-year survival rates below 50% 
(134, 135). Generally, patients with early-stage tumors often undergo surgical 
excision alone or radiation therapy alone with curative intent, which can be 
achieved in up to 90 pe rcent of patients with stage I disease and more than 60 
percent of those with stage II disease (8). For patients with local regionally 
advanced diseases (stage III o r IV), combined modality therapy has been 
developed as the standard of care. The major strategies include concomitant 
administration of chemotherapy and radiotherapy (chemoradiotherapy), induction 
(neoadjuvant) chemotherapy followed by s urgery or radiotherapy, and adjuvant 
chemotherapy after the patient has been rendered free of disease (7, 136, 137). 
However the prognosis for the patients with locally advanced HNSCC is usually 
poor, that majority of them will ultimately develop local recurrence or distant 
metastatic disease (8, 136). Cisplatin (cis-dichlorodiammineplatinum (II)) has 
been approved by Food and Drug Administration (FDA) for the treatment of 
HNSCC since 1970s, and still remains as the standard and first-line chemotherapy 
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in treating HNSCC although many other agents such as 5-fluorouracil, bleomycin, 
docetaxel and methotrexate, and have been extensively studied (138, 139). In 
recent years, modulation of the dysregulated EGFR has been successfully 
exploited for the treatment of HNSCC, novel agents of such purpose include 
monoclonal antibodies (cetuximab, panitumumab) which target the extracellular 
domain of EGFR, and small molecule tyrosine kinase inhibitors (TKIs) (erlotinib, 
gefitinib) that target the intracellular EGFR domain (139-141).  
 
1.2.7 Drugs in the clinical trials 
Several clinical trials are currently being carried out using number of 
pharmacological agents for HNSCC treatment. Few such trials are listed briefly in 
Table 1. Although cetuximab has been approved by FDA, there are still several 
ongoing Phase III t rials run in new patient populations to broaden and diversify 
the base of evidence supporting the use of cetuximab (135). A fully humanized 
IgG2 antibody panitumumab which differs from cetuximab in both efficacy and 
tolerability has just entered Phase III e valuation in HNSCC (142). Anti-
angiogenic therapies have been approved in treating several solid tumors 
including non-small-cell lung carcinoma (NSCLC), and are being assessed in the 
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context of HNSCC (143). The therapies include VEGF ligand-targeted 
monoclonal antibody bevacizumab and small molecule VEGFR targeted TKIs 
such as vandetanib, sunitinib and sorafenib which possess multikinase inhibiting 
activity. Apart from the above mentioned drugs, there are several other agents in 
clinical trials including but not limited to those that target the signaling cascades 
involved in the pathogenesis of HNSCC (Akt inhibitor Perifosine, Src inhibitor 
Dasatinib and Saracatinib) (144, 145), gene therapy (Gendicine) which uses 
recombinant adenovirus encoding human p53 t umor suppressor gene (rAd-p53) 
(146), and HPV peptide epitope vaccine against HPV positive HNSCC (147). 
Despite the availability of various pharmacological agents, unfortunately, 
majority of the patients relapse after initial response or develop resistance to 
chemotherapy. Moreover, most of the drugs lead to frequent and severe side 
effects such as n ausea, vomiting, mucositis, infusion reaction, dermatological 
toxicity, neurotoxicity, and renal dysfunction that compromise the quality of life 
(QOL) of the patients (148-150). For the above reasons, novel agents with lower 
toxicity which can enhance the effects of current chemotherapeutic drugs and 
overcome the chemoresistance are urgently required. 
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1.2.8 HNSCC animal models  
Animal models that resemble similar biological system to human are 
invaluable in the drug discovery research in understanding biochemical and 
disease pathways, target identification and validation, and developing new 
therapeutic strategies (151). The use of appropriate animal models in the study is 
essential since different models have their own advantages and disadvantages. 
The most commonly used model is the subcutaneous transplanted xenograft of 
HNSCC in athymic nude mice or severe combined immunedeficient (SCID). 
Human tumor cells can be tolerated by the compromised immune system in nude 
mice that enables such cross-species "xenografted" tissues (152). Thus, the 
subcutaneous xenografts are easy to establish and allow easy monitoring of tumor 
growth and end point study. However, the tumors are not locally invasive and do 
not metastasize when placed subcutaneously in nude mice, thus they do not 
present the aggressiveness of the disease which are commonly seen in human. To 
improve the system, orthotopic xenograft models have been introduced, and the 
pathology and host microenvironments of HNSCC are more closely mimicked by 
implanting tumor cells into the original anatomical sites. A number of studies 
have established orthotopic models of sublingual model of squamous cell 
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carcinoma of the oral tongue (SCCOT) through injection of human cell lines or 
human tumor specimens into the oral tongue of nude mice, which led to the 
cervical lymph node and pulmonary metastasis (153-155). Besides the easily 
accessible oral tongue, few other orthotopic models of HNSCC have been 
developed, including that of a thyroid carcinoma by injecting cancer cells into the 
thyroid gland (156), model of sinonasal malignancy with a human epidermoid 
tumor cell lines injected into the maxillary sinus (157), and a model of salivary 
cancer in the parotid glands of nude mice (158). Compared to subcutaneous 
xenograft, orthotopic xenograft models are more technically challenging to 
establish and may result in animal morbidity and even death, and also bring 
difficulty in continuous evaluation for poorly accessible orthotopic sites. Despite 
the conveniences, these xenograft models have several shortcomings. For 
example, lack of a competent immune response in the host precludes the study of 
the important interactions between the experimental therapeutic regimens and a 
functional host immune system. Most importantly, these systems are not able to 
recapitulate the multistep carcinogenesis nature and the heterogeneity of the 
disease in the complex and evolving tumor-host stroma interactions (159). In 
order to study tumor tissue in an immunocompetent environment, syngeneic 
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animal models are generated; the establishment of the model involves the 
transplantation of tumor cells which are genetically identical (syngeneic) to the 
recipient animal into an immunologically competent animal environment. This 
model has been utilized for a variety of studies, including the evaluation of novel 
chemotherapeutic regimens such as vitamin D analogues and lactoferrin (160, 161) 
and immunotherapeutic strategies using IL-12 and IL-2 (162). The main 
disadvantages of the syngeneic tumor models are that they are derived from 
homozygously inbred mice and therefore do not represent the complexity of 
human tumors (163). Another widely used HNSCC models in vivo are the 
chemically-induced cancer models which employ the direct application of a 
potent chemical carcinogen to induce HNSCC tumor formation in 
immunocompetent animals. Carcinogen 7, 12-dimethylbenz[a]anthracene 
(DMBA)-induced Syrian hamster cheek pouch model and 4-nitroquino-line-1 
oxide (4-NQO)- induced oral carcinogenesis model are the two dominant models 
applied in multiple studies of cancer biomarkers, therapeutic modalities and 
strategies as well as chemopreventive agents (164, 165). To develop the 
chemically-induced model, exposure to carcinogens for long durations are 
required and the tumor formation usually takes about 20 to 28 weeks with fairly 
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low frequency, and also the tumors do not  resemble the aggressive features of 
HNSCC seen in human (165). Genetically engineered mouse models especially 
the inducible transgenic mouse models provide have advanced the understanding 
of tumorigenesis in the study of HNSCC. Examples of these elegant approaches 
include inducible TGF-β1 transgenic mice using progesterone receptor (PR) 
system (166), and conditional knockout of TGF-β type II receptor (TGFβRII) and 
conditional “knock-in” of oncogenic K-ras (KrasG12D) in Cre/LoxP system (167, 
168).  
 
1.3 Identification of garcinol as a potential anti-cancer agent 
Natural products for ancient medical uses such as t raditional Chinese 
medicine (TCM) and Ayurveda practiced in India are gaining recognition by the 
scientific and medical communities in the Western world in recent years (169, 
170). These bioactive plants-derived compounds could offer rich and powerful 
sources of therapeutic leads for the drug development (169, 171), and provide 
effective alternative strategies because of the better understanding of their cellular 
targets and mechanisms of action (170). Over the course of last decade, several 
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natural compounds have shown significant therapeutic efficacy in clinical trials 
conducted on cancer patients as indicated in Table 2.  
Garcinia indica, commonly known as Mangosteen, presents many culinary, 
pharmaceutical and industrial uses (172). The spice kokum which is derived from 
this plant has been used traditionally in tropical areas as food ingredient, and also 
as Ayurvedic medicine, for the treatment of diseases as diverse as rheumatism, 
edema, ulcer and infectious diseases (173). Garcinol, a poly-isoprenylated 
benzophenone, is one of the major active compounds extracted from the dried 
rind of the fruit of Garcinia indica tree, has been reported to have anti-oxidative, 
anti-ulcer, anti- microbial, and anti-inflammatory activities (174-177). Along with 
the above effects, garcinol exhibits significant anti-neoplastic and 
chemopreventive roles in a variety of tumor cell lines and in vivo cancer models, 
identified by increasing number of studies in recent years. 
 
Figure 1.1. Fruit of Garcinia indica (left panel) and the chemical structure of 
garcinol (right panel) 
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1.3.1 Major molecular targets of garcinol 
1.3.1.1 CBP/p300 Histone acetyltransferase 
Histone acetyltransferase (HATs) refers to a group of enzymes which 
transfer an acetyl group from acetyl-CoA onto lysine residues on histones. 
Acetylation results in the neutralization of conserved lysine residues on the N-
terminal tails of the core histones, that leads to the changes of histone: DNA and 
histone:histone interactions (178). Such conformational alteration renders DNA 
more accessible to transcriptional regulators (179). HATs work in concert with 
histone deacetylases (HDACs) that interplay with other regulators to maintain 
histone acetylation levels, and the acetylation defects owing to the altered HAT 
and HDAC activities can lead to several diseases, including cancer (180, 181). 
Besides the intrinsic acetyltransferase role, the major HATs cyclic AMP response 
element-binding protein (CBP)/p300 family proteins, function as factor 
acetyltransferases (FATs) to participate in transcriptional regulation by 
acetylating transcription factors such as p53, GATA-1 and c-Myb (182, 183). 
CBP/p300 has been found to be associated with tumor suppression which 
evidenced by the growth suppression functions of CBP/p300, loss or deregulation 
of CBP/p300 activity in various tumors and its role in maintaining the proper 
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functioning of other tumor-suppressor proteins (184, 185). However, the tumor-
suppressor function of CBP/p300 has been questioned by t he observation of 
proliferation defects in CBP/p300 null cells, activation of senescent or cell cycle 
arrest in the absence of CBP/p300 and its contribution to aberrant growth in 
certain leukemias through gain of function mutations (185-187). 
Balasubramanyam et al. has demonstrated the garcinol can specifically 
inhibit the histone acetylation by p300 a nd p300/CBP Associated Factor 
(PCAF) in vitro as well as in vivo in Hela cells (188). The inhibition of 
acetylation in vivo by garcinol altered global gene expression with majority down-
regulated, further microarray analysis revealed that garcinol repressed the 
expression of several proto-oncogenes, suggesting that garcinol may function as 
an anti-cancer compound. Garcinol is able to reprogram key histone and p53 post-
translational modifications (PTMs) via modulating the expression of chromatin 
modifying enzymes in MCF7 cells (189). The garcinol-induced p300 degradation 
led to forkhead box P3 (FOXP3) hypo-acetylation, implying that garcinol could 




1.3.1.2 NF-κB  
Inflammation is a critical component of neoplastic progression that 
contributes to multiple aspects of tumor development including proliferation, 
survival and migration (191), and NF-κB is identified as a key mediator of 
inflammation-induced tumor growth and progression (108). The anti-
inflammatory effects of garcinol has been evaluated in various inflammatory and 
tumor models and have been found to be mediated through the suppression of NF-
κB activation. In an early study, garcinol has been found to suppress LPS and 
IFN-γ induced inflammatory mediators such as inducible nitric oxide synthase 
(iNOS) and COX-2 in macrophage RAW 264.7 cells (192), and such anti-
inflammatory effect of garcinol was attributed to the inhibition of LPS-induced 
NF-κB activation (177). Several lysine residues on p65 could undergo acetylation 
modification by t he coactivator of p300 or PCAF thereby regulating NF-κB 
activation (193-195). As a naturally occurring cell-permeable HAT inhibitor, it is 
not surprising that garcinol has been found to significantly reduced the acetylation 
level of NF-κB, but has no obvi ous effects on the two NF-κB-regulated pro-
inflammatory cytokines TNF-α and IL-6 (196). However, it has been reported 
recently that garcinol significantly decreased the pro-inflammatory mRNA 
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expression of COX-2, iNOS and IL-6, and IL-6 secretion by s uppressing 
phosphorylation of IκBα and p65 (197). It has been also found that garcinol 
inhibits cell proliferation and promotes apoptosis through the negative regulation 
of NF-κB signaling cascade in various types of cancers, such as breast cancer, 
pancreatic adenocarcinoma, and prostate cancer (198-200). Garcinol also causes 
reversal of epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial 
transition (MET) and inhibits the invasion capacity of invasive breast cancer cells 
MDA-MB-231 and BT-549, and forced overexpression of NF-κB abrogates the 
garcinol-induced MET, induction of apoptosis, and inhibition of invasion (201). 
The detailed molecular mechanism(s) underlying garcinol-modulated NF-κB 
activation are not clear yet. However, it has been proposed that garcinol interrupts 
LPS binding to its toll-like receptors, thus affecting the downstream molecules in 
NF-κB activation cascade (202). Another study has suggested that garcinol blocks 
NF-κB translocation through suppressing the phosphorylation of IκBα mediated 





Garcinol has been found to modulate STATs signaling pathways in several 
studies. High interaction affinity of garcinol towards STAT1 protein has been 
demonstrated using surface plasmon resonance and molecular docking studies 
(203). Garcinol is able to inhibit IFN-γ-induced STAT1 activation, nuclear 
translocation and DNA binding activity in MDA-MB-231 cell (203). Similarly, 
garcinol suppresses the iNOS expression and nitric oxide (NO) by inhibition of 
Janus kinase (JAK)/STAT1 signaling in RAW 264.7 cell (202). Ahmad and his 
colleagues have reported the STAT3 inhibitory effects of garcinol in breast, 
prostate and pancreatic cancers (204). However, the in depth molecular 
mechanism(s) by w hich garcinol modulates STAT3 signaling pathway is not 
known yet. 
 
1.3.1.4 Arachidonic acid metabolism 
Aberrant arachidonic acid metabolism is involved in inflammation and 
carcinogenesis owing to the tumor promoting activities of the metabolic products 
prostaglandins (PGs) and leukotrienes (205, 206). Pharmacological intervention in 
the biosynthesis of these metabolites by inhibiting the relevant enzymes cytosolic 
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phospholipase A2 (cPLA2), COXs and lipoxygenases (LOXs) has been considered 
an effective approach for cancer chemoprevention and treatment (207-209). 
Garcinol has been shown to significantly inhibit the release of arachidonic 
acid and its metabolites in macrophages by retarding the phosphorylation of 
cPLA2 and suppressing COX-2 expression (202). However, Koeberlea and 
coworkers have demonstrated that garcinol selectively inhibits the activity of 
COX-1, with no s ignificant reducing of COX-2 activity (210). They also found 
that garcinol potently interferes with 5-LOX and microsomal prostaglandin E 
synthase-1 (mPGES-1) to inhibit the enzymatic activities and biosynthesis of their 
enzymatic products leukotriene and PGE2 in cell-free system as well as in A549 
human lung carcinoma cells (210). In a later study, using computer modeling 
analysis it was found that garcinol could fit well into the active site of 5-LOX, and 
potentially inhibit the enzyme activity through interactions between the phenolic 
hydroxyl groups and the non-heme catalytic iron (211). Chen and coworkers 
further tested the 5-LOX inhibitory activities of garcinol in DMBA-treated 
hamster cheek pouch model and showed that garcinol suppressed leukotriene B4 
biosynthesis, inhibited inflammation, and reduced the number and size of 
carcinogen induced-tumors (211). 
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1.3.1.5 Other important molecular targets modulated by garcinol 
MAPK signaling pathways are evolutionarily conserved signaling 
molecules that regulate the fundamental cellular processes such as cell growth, 
proliferation, differentiation, migration and apoptosis in response to stress stimuli 
and inflammation (212). Despite the negative regulation role of p38-MAPK in 
cell cycle progression (213), emerging evidences show that p38 a ctivation 
positively regulates proliferation, leads to increased survival and mediates 
metastasis in malignant cells; and several p38 inhibitors are effective in animal 
models and have advanced to clinical trials for the treatment of cancer (214). It is 
reported that garcinol significantly suppressed the activation of p38-MAPK, 
leading to the abrogation of inflammatory response of genes depending on NF-κB 
activation in macrophages (177). In lung cancer cell H1299, garcinol-induced 
inhibition of p38-MAPK activation upregulated p21Waf1/Cip1 expression, resulted 
in G1 cell cycle arrest (215). 
Altered activity of an important mediator of growth factor signaling, cell 
proliferation, survival and migration, focal-adhesion kinase (FAK), usually 
contributes to the development of various malignancies (216). Garcinol has been 
shown to suppress the activity of FAK signaling in human colon carcinoma cell 
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HT-29 and subsequent alteration of Bcl-2/Bax ratio and reduction of 
proteolytically active matrilysin (MMP-7) which accounts for its ability to induce 
apoptosis and inhibit cellular invasion (217). 
MicroRNAs (miRNAs) are a class of small RNA (similar to 22 nucleotides) 
molecules which do not encode protein, but function directly as regulatory RNAs 
in various aspects of animal development through post-transcriptional 
modification (218). Number of these evolutionarily conserved miRNAs have been 
shown to modulate mammalian cell growth, differentiation and apoptosis (219), 
and implicated to act as oncogenes and/or tumor suppressors regulating these 
processes in various cancers (220). The garcinol mediated mesenchymal-
epithelial transition observed in aggressive breast cancer has been associated with 
the upregulation of miR-200 and let-7 family miRNAs upon garcinol treatment 
(201). In a recent study, garcinol alone or in combination with gemcitabine has 
been found to alter microRNA profile in human pancreatic cancer cell line Panc-1 
that might target key cancer pathway signaling molecules (221).  
Wnt/β-catenin signaling is essential for stem cell function and 
embryogenesis by r egulating the change of embryonic epithelial cells to 
mesenchymal derivatives (222), and perturbations in Wnt signaling promotes 
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tumor EMT during cancer progression (222, 223). Recently, garcinol has been 
found to upregulate glycogen synthase kinase-3β (GSK-3β), along with the 
increasing levels of β-catenin phosphorylation, resulting in the inhibition of 
nuclear translocation of this key mediator of the Wnt signal in breast cancer 
MDA-MB-231 and BT-549 cells (201). 
Besides the nervous system, nicotinic acetylcholine receptors (nAChRs) 
have been found to be universally expressed in mammalian cells, including 
multiple types of cancer (224, 225). Emerging evidences have shown that altered 
signaling of nAChRs promotes smoking-induced cancer formation by regulating 
the release of growth, angiogenic and neurogenic factors and stimulating signal 
transductions (226). Chen and colleagues have demonstrated that garcinol 
attenuated the nicotine-induced human breast cancer cell proliferation through 





1.3.2 Anti-cancer effects of garcinol in vitro 
1.3.2.1 Garcinol induces cell cycle arrest 
Cancer cells possess altered cell cycle kinetics to sustain the uncontrolled 
growth, thus the therapeutic agents that can modulate cell cycle progression are of 
great potential for cancer treatment. Gacinol has been found to induce G0/G1 
phase cell cycle arrest in MDA-MB-231 cells through suppressing nicotinic 
receptor and down-regulation of D-type cyclins (227). While garcinol-induced 
p53-independent G1 cell cycle arrest in H1299 cells is associated with the 
upregulation of CDK Inhibitors p21Waf1/Cip1 and p27Kip1 (215). Garcinol has been 
shown to cause reduction in the numbers of actively replicating cells (S phase) 
and concomitant increase in the G1 population in MCF7 cell, possibly through the 
inhibition of CBP/p300, or other HATs required for progression through S phase 
(189). Garcinol also facilitates senescence of A549 lung carcinoma cells through 
inhibiting double-strand break repair, including non-homologous end joining 




1.3.2.2 Garcinol induces apoptosis  
It is now well established that apoptotic pathways contribute to the 
cytotoxic action of most chemotherapeutic drugs through either extrinsic pathway 
initiated by death receptors, or intrinsic pathway which involves disruption of the 
mitochondrial membrane and the release of mitochondrial proteins (229, 230). 
Garcinol engages both pathways to induce the programmed cell death in a variety 
of neoplastic cells (231, 232). Garcinol has been shown to induce both of the 
TNF-related apoptosis-inducing ligand (TRAIL), death receptor 4 (DR4) and DR5 
in a wide variety of cells including colon, breast, prostate, kidney, leukemic, and 
esophageal cancer cells, and subsequent activation of caspase-8 and downstream 
caspase cascades and apoptosis (231). The above mentioned upregulation of DR4 
and DR5 by garcinol was mediated by a substantial increase in reactive oxygen 
species (ROS) generation. Garcinol could also cause the accumulation of ROS, 
increase growth arrest and DNA damage-inducible gene 153 ( GADD153) 
expression and further resulted in downstream apoptotic events in hepatocellular 
carcinoma Hep3B cells (233). However, in another study, garcinol has been 
shown to reduce the LPS-induced increase of intracellular ROS involved in the 
activation of NF-κB (177). In addition, garcinol downregulated various cell 
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survival proteins including survivin, Bcl-2, X-linked inhibitor of apoptosis 
protein (XIAP), and c-FLIP and disrupted mitochondrial homeostasis through 
cleavage of bid, increasing pro-apoptotic bax expression and cytochrome c release 
that further contributed to enhanced apoptosis (231). These findings are in line 
with the observations from several reports indicating that garcinol exerts its 
apoptosis-inducing effects in a wide range of tumor cells through possible 
garcinol-induced modulation of important signaling cascades such as FAK, 
MAPK/ extracellular signal-regulated kinase (ERK), PI3K/Akt, NF-κB and 
JAK/STAT and their regulated gene products (198, 217, 221, 234).  
 
1.3.2.3 Garcinol potentiates the effects of chemotherapeutic agents 
Drug combination therapies are emerging as p romising strategies to 
improve therapeutic efficacy, tackle the problem of drug-related toxicity and 
major side effects, and overcome the chemoresistance (235, 236). Garcinol has 
been tested in combination with multiple agents in different tumor cells and 
displayed enhanced effect (221, 231, 237). Garcinol sensitized human pancreatic 
adenocarcinoma cells to the standard clinical chemotherapeutic agent gemcitabine 
that attenuated the drug-resistance phenotype (221). The same group has applied 
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garcinol together with another widely studied natural product curcumin, and 
observed synergistic effects in reduction of cell viability and increase of apoptosis 
in BxPC-3 and Panc-1 cells (237). Agonistic monoclonal antibodies to the TRAIL 
receptors and recombinant TRAIL are being developed in clinical trials as TRAIL 
selectively activate death receptors and induces apoptosis of a variety of tumor 
cells (238, 239). Prasad and his group have reported that garcinol could potentiate 
TRAIL-induced apoptosis in colon cancer HCT116 cells and sensitize TRAIL-
resistant HT29 cancer cells to TRAIL (231). 
 
1.3.2.4 Garcinol potentiates the effects of radiotherapy 
The widely used ionizing radiation (IR) in the treatment of human cancers 
exerts the cytotoxic effects by producing DNA double-strand breaks, but usually 
the IR-induced double-strand breaks are preferentially repaired by non-
homologous end joining that confers chemoresistance (240, 241). Garcinol 
specifically sensitizes cancer cells to radiotherapy with dose enhancement ratios 
by inhibiting NHEJ and also augments IR-induced senescence (228). In a study, it 
has been found that garcinol presents strong radiosensitizing effect comparable to 
the well-known radiosensitizers that target DNA repair proteins, such as poly 
41 
 
(ADP-ribose) polymerase (PARP) inhibitor olaparib, and DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs) inhibitor NU7026 (242). 
 
1.3.2.5 Garcinol inhibits tumor cell invasion and migration 
The ability of garcinol to impede cell invasive capacity and migration has 
been reported in different cell lines and linked to several cancer signaling 
molecules. Garcinol inhibited cellular invasion in HT-29 cells through reduction 
of FAK tyrosine phosphorylation, and suppressing the downstream pathways for 
proteins associated with the focal adhesion complex (217). The reduced invasion 
and aggressiveness of cells after garcinol treatment have been observed in other 
tumor cell lines such as breast cancer (MDA-MB-231), prostate cancer (DU145) 
and pancreatic cancer (BxPC-3), and these effect have been found to be 
associated with garcinol-induced inhibition of STAT3 signaling and 
downregulation of its downstream targets urokinase-type plasminogen activator 
(uPA) and MMP-9 (204). Ahmad and his coworker suggested the garcinol-
induced inhibition of invasion in aggressive breast cancer cells MDA-MB-231 
was due to reversal of EMT phenotype which is mechanistically linked with the 
deregulation of miR-200s, let-7s, NF-κB, and Wnt signaling pathways (201). In 
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addition to invasion, garcinol also hindered migratory potential of BxPC-3 and 
Panc-1 cells, by suppressing NF-κB mediated MMP-9, IL-8 and PGE2 expression 
(199). Although there are no concrete evidence(s) to show that garcinol can also 
modulate neovascularization, several studies have reported that garcinol 
donwregulated the expression of key angiogenic factor VEGF, suggesting the 
anti-angiogenic potential of garcinol (199, 204, 221, 234). 
 
1.3.3 Anti-cancer effects of garcinol in vivo 
Pre-clinical animal models are indispensable and invaluable tools in 
predicting drug efficacy and toxicity in drug development. There are several 
reported in vivo studies elaborating the potential therapeutic effects of garcinol in 
diverse animal models. 
1.3.3.1 Garcinol inhibits tumor growth in vivo 
Immunohistochemical analysis of tumor tissues from garcinol treated 
breast cancer cell xenograft mice revealed that garcinol inhibited the tumor cell 
proliferation and microvessel density as evidenced by the downregulation of Ki-
67 and CD31 expression (201). The same group found that garcinol can 
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significantly reduce the tumor growth in mice MDA-MB-231 cells xenografts 
(204).  
 
1.3.3.2 Garcinol enhances the anti-tumor effects of targeted therapies in vivo 
Garcinol has also been evaluated in drug combination study using 
syngeneic tumor mouse model. Garcinol was observed to enhance the in vivo anti-
tumor activity of a targeted therapeutic anti-p185her2/neu antibody in BALB/c mice 
implanted with neu transformed mouse breast tumor cells H2N113, while either 
agent alone only modestly reduced the tumor growth (190). 
 
1.3.3.3 Garcinol as a cancer chemopreventive agent in vivo 
A number of dietary phytochemicals are being studied and evaluated in 
intervention trials for chemoprevention of cancers, as an inexpensive, readily 
applicable, acceptable and accessible approach to cancer control and management 
(243, 244). Garcinol has been investigated for its chemopreventive potential in 
several chemically-induced cancer models. Dietary administration of garcinol 
caused significant reduction in the frequency of azoxymethane (AOM)-induced 
colonic aberrant crypt foci (ACF) in male F344 rats (192). Garcinol also exhibited 
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chemopreventive potential against HNSCC in vivo, specifically, dietary garcinol 
significantly decreased the incidence and multiplicity of 4-NQO-induced tongue 
neoplasms and/or pre-neoplasms in F344 rats(245), and topical application 
of garcinol on DMBA-treated hamster cheek pouch significantly reduced the size 
of visible tumors, and the number of cancer lesions (211). 
 
1.3.4 Pharmacokinetic studies with garcinol 
No prior reports have conducted detailed pharmacokinetic studies of 
garcinol in animals. Only one study has indicated that peak concentration of 
garcinol reached 12 and 2.7 µ M in plasma and urine respectively, after oral 
gavage of garcinol (10 mg dose per mouse) into CD-1 female mice (202). 
 
1.3.5 Toxicological analysis of garcinol 
Garcinol has been tested in several animal models through different 
administration modes including intraperitoneal injection, oral gavage, topical 
application and dietary administration (190, 204, 211, 245). So far, no obvi ous 
toxic effects caused by garcinol in these models have been reported as evidenced 
by the absence of body w eight loss and pathological alterations in important 
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organs such as liver, kidney, lung and heart (192, 211, 245). However, no 


















2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Reagents and chemicals 
Cisplatin, dimethyl sulfoxide (DMSO), thiazoyl blue tetrazolium bromide 
(MTT), sodium dodecyl sulfate (SDS), dimethylformamide (DMF), propidium 
iodide (PI), sodium chloride (NaCl), HEPES, EDTA, triton X-100, aprotinin, 
leupeptin, phenylmethylsulfonylfluoride (PMSF), sodium pervanadate (Na3VO4), 
tris, glycine, bovine serum albumin (BSA), β-actin antibody, acetone, 4’,6-
diamidino-2-phenylindole (DAPI), and mounting medium were bought from 
Sigma-Aldrich Co. (St. Louis, MO, USA). Garcinol with high purity (> 98%) was 
extracted from the rind of Garcinia indica fruit as d escribed previously (188). 
Dulbecco’s modified Eagle medium (DMEM), DMEM/F12, fetal bovine serum 
(FBS), L-glutamine, non-essential amino acid (NEAA), sodium pyruvate, 
vitamins, antibiotic-antimycotic mixture, trypsin, trypan blue vital stain, 
Lipofectamine® 2000, TRIzol ® reagent, Alexa Fluor® 594 goat anti-rabbit 
immunoglobulin G (IgG), and Click-iT® Plus EdU Flow Cytometry Assay Kit 
were purchased from Life Technologies (Carlsbad, CA, USA). Annexin V-FITC 
assay kit, antibodies against phospho-specific STAT3 (Ser 727), caspase-3, PARP, 
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cyclin D1, cyclin E, p27, Mcl-1, Bcl-xL, Bcl-2, survivin, FLIPS/L, Bak, Bax, 
VEGF, MMP-2, ICAM-1, SHP2, PTP1B, PTEN, p65, I κBα, GAPDH, COX-2, 
Ki-67, goat anti-mouse HRP secondary antibody, and goat anti rabbit HRP 
conjugate were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). 
Antibodies against phospho-specific STAT3 (Tyr705), phospho-specific JAK1 
(Tyr 1022/1023), phospho-specific JAK2 (Tyr1007/1008), phospho-specific Src 
(Tyr416), phospho-specific p65 ( Ser536), phospho-specific IκBα (Ser 32), 
phospho-specific TAK1 (Thr 187), phospho-specific IKKα/β (Ser 180 /Ser 181), 
phospho-specific mTOR (Ser2448), phospho-specific AKT (Ser 473), phospho-
specific p70S6K (Thr 389), XIAP, caspase-8, caspase-9, MMP-9, STAT3, SHP1, 
Src, JAK1, JAK2, lamin B1, TAK1, IKKα, mTOR, AKT, p70S6K, and CD31 
were obtained from Cell Signaling Technology (Danvers, MA, USA). Phospho-
specific SHP1 (S591), phospho-specific SHP1 (Y536) and CXCR4 antibodies 
were purchased from Abcam (Cambridge, MA, USA). The cell Death Detection 
ELISAPLUS Kit was obtained from Roche Diagnostics (Indianapolis, IN, USA). 
Recombinant human IL-6, EGF, and CXCL12 (stromal cell-derived factor-1; 
SDF-1) were purchased from ProSpec (Israel). Bradford reagent was obtained 
from Bio-Rad Laboratories (Hercules, CA, USA). Blocking One reagent was 
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purchased from Nacalai Tesque (Kyoto, Japan). Western Bright Sirius HRP 
substrate was purchased from Advansta (Menlo Park, CA, USA). Bright-Glo™ 
Luciferase Assay System was purchased Promega (Madison, WI, USA). Trans 
AM™ nuclear extraction kit and STAT3/NF-κB Transcription Factor DNA-
binding Kits were purchased from Active Motif (Carlsbad, CA, USA). Primers 
and probes for human Bcl-2, Mcl-1, Bcl-xL, survivin, VEGF, and cyclin D1 were 
obtained as kits from Applied Biosystems® Life Technologies. The 
immunohistochemistry (IHC) DAKO LSAB kit was purchased from Dako 
Corporation (Carpinteria, CA, USA). 
 
2.1.2 Cell lines 
Human HNSCC cell line UMSCC1 was kindly provided by Prof. Thomas E. 
Carey (University of Michigan, Ann Arbor, MI, USA) and have been 
characterized previously. MDA686Tu, MDA686LN, and Tu138 were kindly 
provided to us by Prof. Jeffrey N. Myers (The University of Texas MD Anderson 
Cancer Center, Houston, Texas, USA) and have been characterized previously. 
CAL27 was purchased from American Type Culture Collection. UMSCC1 and 
CAL27 were cultured in DMEM supplemented with 100 U/mL penicillin, 100 
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μg/mL streptomycin and 10% FBS. MDA686Tu and MDA686LN were cultured 
in DMEM supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 10% 
FBS, 2mM glutamine 1× NEAA, 1× sodium pyruvate, and 1× vitamin. Tu138 
was cultured in DMEM/F12 supplemented with 10% FBS, 100 U/mL penicillin, 
100 μg/mL streptomycin, and 2 mM glutamine. All the cell lines used were grown 













2.2.1 MTT cell viability assay 
MTT assay was used to examine the effect of garcinol on HNSCC cell 
viability. Briefly HNSCC cells (1×104/mL) in a volume of 200 µL were incubated 
in 96-well plates with different concentrations for the indicated time points. Then, 
20 µL of MTT solution (5 mg/mL) was added, after which the plates were 
incubated for 2 h  at 37˚C to allow converting of MTT to its insoluble purple 
formazan by NAD(P)H-dependent cellular oxidoreductase enzymes in 
metabolically intact cells. After removal of the medium, the purple formazan 
crystals formed were dissolved in 100 µL lysis buffer (50% DMF, 20% SDS) 
with 1h incubation at 37˚C. The optical density (OD) of dissolved purple crystal 
was measured by Safire2™ microplate reader (Tecan Group, Männedorf, 
Switzerland) at 570 nm. 
 
2.2.2 EdU cell proliferation assay 
Click-iT® Plus EdU Flow Cytometry Assay Kit (Life Technologies, 
Carlsbad, CA, USA) was used to measure HNSCC cell’s ability to proliferate 
with or without garcinol treatment. Briefly, CAL27 cells (5×105/mL) were treated 
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with 15 µM and 25 µM garcinol for 12, 24, and 48 h. The cells were pulse labeled 
with 10 µ M 5-ethynyl-2’-deoxyuridine (EdU; thymidine analog) for 2 h, 
thereafter cells were trypsinized, washed with PBS, and fixed with Click-iT® 
fixative. After washing with PBS, the cells were permeabilized with Click-iT® 
saponin-based permeabilization and wash reagent. Then, the Click-iT reaction 
was allowed after incubation with Click-iT® Plus reaction cocktail to label the 
EdU- incorporated cells with Alexa Fluor® 488 dye. Standard flow cytometry 
method was used for determining the percentage of S-phase cells in the 
population using CyAn™ ADP Analyzer (Dako Corporation, Carpinteria, CA, 
USA). 
 
2.2.3 Cell cycle analysis by flow cytometry 
HNSCC cells (5×105/mL) were seeded and then synchronized by 
starvation in serum-free medium for 24 h. Upon completion of 25 µM garcinol 
treatment for 12, 24, and 48 h, the cells were collected following trypsinization, 
and then fixed with ice-cold 70% ethanol for 30 min. The fixed cells were washed 
with PBS, treated with RNase A (1 µg/mL), and stained with propidium iodide 
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(10 µg/mL) protected from light for 30 min. DNA contents of the samples were 
analyzed using CyAn™ ADP Analyzer. 
 
2.2.4 Enzyme-linked immunosorbent assay (ELISA) for DNA fragmentation 
detection  
Cell Death Detection ELISAPLUS kit (Roche Diagnostics, Indianapolis, IN, 
USA) was used for DNA fragmentation detection as described previously. Briefly, 
HNSCC cells (5×105/mL) were exposed to 25 µM garcinol for 12, 24, a nd 48 h. 
After the incubation, the cytoplasmic fractions were extracted and transferred into 
the streptavidin-coated microplate incubated with the biotinylated histone 
antibody and anti-DNA-peroxidase conjugate for 2 h a t room temperature. The 
photometric signals were determined by measuring absorbance at 405 nm after 
adding ABTS substrate. The enrichment of mono- and oligonucleosomes released 





2.2.5 Apoptosis detection by Annexin V staining 
The apoptosis inducing effect was further evaluated by Annexin V-FITC 
assay kit. Briefly, HNSCC cells (5×105/mL) were exposed to 25 µM garcinol for 
12, 24, and 48 h, and then harvested and washed with PBS. The prepared cells 
were resuspended in binding buffer followed by incubation with annexin V-FITC 
and PI for 15 min in darkness. The apoptotic index was immediately determined 
by flow cytometry using CyAn™ ADP Analyzer. 
 
2.2.6 Western blot analysis 
To prepare the whole cell protein extracts, cells were collected by scraping, 
and then lysed in lysis buffer containing NaCl (250 mM), EDTA (2 mM, pH 8.0), 
EGTA (0.5 mM), HEPES (20 mM), 0.1% Triton X-100, aprotinin (1.5 µg/mL), 
leupeptin (1.5 µg/mL), PMSF (1 mM), and sodium orthovanadate (1.5 mM). 
After incubation on i ce for 15 min, lysed cells were then centrifuged at 13,300 
rpm for 10 m in to pellet debris. Cellular proteins were separated on 8%, 10%, 
12%, or 15% SDS-PAGE gel, and then transferred onto nitrocellulose membrane 
(Bio-Rad Laboratories, Hercules, CA, USA). Membranes were placed in blocking 
buffer (Blocking One reagent) for 1 h , followed by incubation with primary 
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antibodies overnight at 4˚C. Appropriate secondary antibodies conjugated to 
streptavidin-HRP were used for signal detection, upon membrane incubation with 
Western Bright Sirius HRP substrate and detection by Molecular Imager® 
ChemiDoc™ XRS System (Bio-Rad Laboratories, Hercules, CA, USA). 
Densitometric analysis of Western blots was performed using Image J so ftware 
and band intensity was normalized to untreated control as fold change. 
 
2.2.7 Immunocytochemistry for STAT3 localization 
HNSCC cells grown in 8-well Nunc Lab-Tek Chamber Slide (Thermo 
Fisher Scientific, Waltham, MA, USA) were exposed to garcinol treatment as 
indicated. Thereafter, the slides were fixed with ice-cold acetone, permeabilized 
in 0.2% TritonX-100, followed by bl ocking in 5% FBS. Primary antibody to 
STAT3 (1:100 dilution) was added onto the cells and left overnight at 4 °C. Cells 
were subsequently incubated with Alexa Fluor® 594 (1:100 dilution) secondary 
antibody for 1 h at room temperature. Staining with 0.5 µg/mL DAPI was done 
for visualization of the cell nuclei. After mounting, the immunofluorescence 




2.2.8 Preparation of cytoplasmic and nuclear extracts 
Nuclear proteins were extracted from cell lines using Trans AM™ nuclear 
extraction kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Briefly, cells were washed with phosphatase inhibitors-containing 
PBS and collected by s craping. After centrifugation at 500 rpm for 5 min, the 
supernatant was discarded and the cell pellet was resuspended with 1× Hypotonic 
Buffer which was then incubated on ice for 15 min. Detergent was added to the 
suspension and vortexed at highest setting for 10 s econds. Supernatant 
(cytoplasmic fraction) was collected after centrifugation and stored at -80˚C. The 
nuclear pellet was resuspended in complete lysis buffer by pipeting up and down. 
After vortexing for 10 seconds, the suspension was incubated for 30 min on ice on 
a rocking platform set at 150 rpm. Suspension was then vortexed again for 30 
seconds and centrifuged at 14,000g for 10 min. Supernatant (nuclear fraction) was 
collected and stored at -80˚C until ready to use. 
 
2.2.9 DNA-binding assay 
The DNA-binding capacity of STAT3 or NF-κB was determined by using 
Trans AM™ STAT3 or NF-κB transcription factor assay kit (Active Motif, 
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Carlsbad, CA, USA) as described previously (234). Briefly, 20 µg of nuclear 
proteins were subjected to binding of STAT3 or NF-κB to an immobilized 
consensus sequence in a 9 6-well plate respectively, and primary and HRP-
conjugated secondary antibodies were added. After incubating with substrate, the 
colorimetric reading at 450 nm was determined in a microplate reader. The 
experiments were carried out according to the manufacturer’s instruction. 
 
2.2.10 RNA extraction and real time PCR  
RNA sample was isolated by TRIzol method. Briefly, after treatment with 
garcinol, HNSCC cells were subjected to homogenization in cold TRIzol reagent. 
Phase separation of the cell suspension was performed after the addition of 
chloroform, followed by RNA precipitation with isopropyl alcohol. The purified 
RNA in the pellet was washed with75 % ethanol, air dried, and dissolved in 
nuclease free water. Total RNA was reverse-transcribed into single-strand 
complementary DNA ( cDNA), thereafter the real time PCR analyses were 
performed in duplicate with Applied Biosystems 7500 Fast Real-Time PCR 
System as described previously (234). Data was evaluated using Sequence 
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Detection Software (Applied Biosystems® Life Technologies), and the 2-ΔΔCt 
formula. 
 
2.2.11 STAT3 luciferase reporter assay 
MDA686Tu (1×104 cells/well) in 96-well were co-transfected of plasmid 
with STAT3-responsive elements linked to a luciferase reporter gene and wild-
type or dominant-negative STAT3 constrcut using lipofectamine® 2000. After 
transfection for 48 h, various concentrations of garcinol were added into the wells 
for 6 h, f ollowed by 6 h incubation with IL-6 or EGF. Luciferase activity was 
determined using Bright-Glo™ Luciferase Assay System from Promega (Madison, 
WI, USA).  
 
2.2.12 Wound-healing migration assay 
The migration of cancer cells was investigated by wound-healing assay 
using IBIDI culture insert (ibidi GmbH, Munich, Germany) consisting of two 
reservoirs separated by a 500 µm thick wall in a 35 mm petri dish. CAL27 cells 
were starved to inactivate cell proliferation and then an equal number of cells (70 
µL; 1×106 cells/mL) were seeded into the two reservoirs of the same insert. After 
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12 h, the insert was gently removed creating a gap of ~500 µm. The cells were 
then treated with garcinol and or CXCL12 as indicated, after which the wound 
closure areas were visualized using bright field microscopy. Wound healing rate 
was calculated as the difference in wound area before and after treatment. 
 
2.2.13 Invasion assay 
BD BioCoat Matrigel Invasion Chamber (BD Biosciences, San Jose, CA, 
USA) assays were done in 24-well plates using polycarbonate inserts with 
Matrigel coating (8-μm pores) to examine in vitro cell invasion. A total 500 µL 
CAL27 cells (5×105 cells/mL) were seeded in the upper compartment of the 
transwell chamber, and treated with 15 μM garcinol for 8 h after which 100 
ng/mL CXCL12 was added into the lower chamber of the 24-well plate for 
additional 24 h i ncubation. Non-invading cells on the upper side of the insert 
membrane were removed using a cotton swab, while invading cells attached to the 
bottom were fixed with 4% paraformaldehyde and stained with crystal violet. 
Multiple images were taken from randomly selected areas under microscopy and 




2.2.14 Xenograft tumor model 
Males, aged five weeks, nu/nu athymic mice (Biological Resource Centre, 
Biopolis, Singapore) were used as xenograft recipients for human HNSCC tumors. 
2×106 CAL27 cells were resuspended in the saline in total volume of 100 μL and 
were then injected subcutaneously into the flank of the animals. When tumors 
reached 0.25 cm in diameter, animals were randomly divided into three 
experimental groups (n = 5, per group), specifically the vehicle-treated control 
and garcinol at a dose of 1 a nd 2 mg/kg (body weight). Garcinol dissolved in 
saline with 0.1% DMSO (100 µL, total volume) was injected in the mice 
intraperitoneally five times a w eek for 4 weeks, while control group received 
injections of 100 µL of vehicle saline buffer. Tumor volume and body weight of 
each mouse were evaluated three twice a week. The diameters of the tumor were 
measured with vernier caliper, after which volume of the tumor was calculated as: 
(longest diameter) × (shortest diameter) 2) × 0.5. Mice were sacrificed 4 weeks 
after initiating treatment, and tumors were excised and either stored at -80 °C for 
western blot or processed and embedded in paraffin for immunohistochemistry 
analysis. All the mouse experiments reported in this study were reviewed and 
approved by NUS Institutional Animal Care and Use Committee. 
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2.2.15 Immunohistochemical analysis of tumor tissues 
Immunohistochemical analysis was carried out on formalin-fixed, 
paraffin-embedded sections of each tumor specimen using the streptavidin-biotin-
peroxidase technique. Briefly, after deparaffinization in xylene, slides were 
rehydrated in graded ethanol and then heated for antigens retrieval, thereafter the 
slides were incubated in 3% hydrogen peroxide to block the endogenous 
peroxidase activity. After blocking in the blocking reagent, the sections were then 
incubated with appropriate primary antibodies (1:100 dilution) overnight, 
followed by incubation with biotinylated linker and then streptavidin-peroxidase 
complex at room temperature. Then the sections were incubated with 3, 30’-
diaminobenzidine tetrahydrochloride (DAB) working solution for color reactions, 
and finally, counterstained with hematoxylin and mounted. Slides were visualized 
using Olympus BX51 microscope at ×20 magnification, and quantitative analysis 
of images was performed using Image-Pro plus software (Media Cybernetics, 




2.2.16 Xenograft tumor model for drug combination study 
Females, aged six weeks, nu/nu athymic mice (Animal Resource Centre, 
Australia) were used as xenograft recipients for human HNSCC tumors. 
3×106 CAL27 cells were resuspended in the saline in total volume of 100 μL and 
were then injected subcutaneously into the flank of the animals. When tumors 
reached 0.25 cm in diameter, animals were randomly divided into five 
experimental groups (n = 5, per group), namely: (I) vehicle-treated control; (II) 
garcinol (0.5 mg/kg body weight); (III) cisplatin (2 mg/kg body weight); and (IV) 
combination of garcinol and cisplatin. Garcinol dissolved in saline with 0.1% 
DMSO (100 µL, total volume) was injected in the mice intraperitoneally five 
times a w eek, cisplatin in saline was injected in the mice intraperitoneally two 
times a week, while control group received injections of 100 µL of vehicle saline 
buffer. Tumor diameters and body weight of each mouse were measured three 
twice a week. Tumor volume was calculated using the formula: (longest diameter) 
× (shortest diameter) 2) × 0.5. Mice were sacrificed 4 weeks after initiating 
treatment, and tumors were excised and either stored at -80 °C for western blot or 
processed and embedded in paraffin for immunohistochemistry analysis. All the 
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mouse experiments reported in this study were reviewed and approved by NUS 
Institutional Animal Care and Use Committee. 
 
2.2.17 Pharmacokinetic study of garcinol in mice 
Pharmacokinetics of garcinol was conducted in nude mice by i.p. injection 
at dose of 0.5 mg/kg or 2 mg/kg. The mice were allowed food and water ad 
libitum before pharmacokinetics experiment. About 150 μL of blood was taken 
from facial vein of mice at 10 min, 30 min, 1, 2, 4, 6, a nd 8 h pos tdose. After 
centrifugation of blood samples at 14,000 rpm at 4°C for 10 min, mouse sera (the 
supernatant) were transferred into eppendorf tube. 10 μL of each serum was 
processed by adding 3-folds excess of acetonitrile-containing isogarcinol, the 
internal standard followed by vortexing for 1 min. The tube was then centrifuged 
at 14,000 rpm at 4°C for 10 min. Then 30 μL of the supernatants were transferred 
into glass inserts (250 μL) with 70 μL of 10 mM ammonia acetate solution. 50 μL 
of processed serum samples were injected into LC-MS/MS which was carried out 
under negative electrospray ionization (ESI) and multiple reaction monitoring 
(MRM) mode. Mass spectra of garcinol and its internal standard, isogarcinol 
showed a same precursor ion [M-H] - at m/z of 601. The daughter ion monitored 
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for garcinol and isogarcinol was 409 and 335, respectively. SCIEX Analyst 
software (version 1.4.2) was used for data acquisition and analysis. 
 
2.2.18 Statistical analysis  
The results were expressed as the means±standard deviations. Quantitative 
variables were compared with Student’s t-test, or analyses of variance (ANOVA). 














3.1 Anti-cancer effects of garcinol on HNSCC cells in vitro 
3.1.1 Garcinol inhibits the viability of HNSCC cells. 
The cytotoxic ability of garcinol was assessed on a panel of diverse HNSCC 
cell lines by the MTT assay. The cells were exposed to various concentrations of 
garcinol for different time interals as indicated and then subjected to MTT assay. 
It is clear from our data that garcinol significantly inhibited the viability of 
CAL27, UMSCC1, MDA686LN, MDA686Tu, and Tu138 cell lines in a time- 
and dose-dependent manner.  
 
Figure 3.1.1. Garcinol suppresses the viability of various HNSCC cells. 
CAL27, UMSCC1, MDA686LN, MDA686Tu, and Tu138 cells (1×104/mL) were 
exposed to 0, 5, 10, 15, 25, and 50 μM of garcinol for 24, 48, and 72 h. Cell 
viability was then analyzed by MTT assay. (*p <0.05) 
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3.1.2 Garcinol suppresses the cell proliferation of HNSCC cells. 
The anti-proliferative effect of garcinol was further evaluated by nuc lear 
EdU incorporation method to measure the DNA synthesis. CAL27 cells 
(5×105/mL) were exposed to 0, 15 and 25 μM garcinol for 12, 24, and 48 h, after 
which the cells were pulse labeled with EdU, a nucleoside analogue to thymidine 
which is incorporated into DNA during active DNA synthesis. Detection is based 
on a click reaction, in which EdU is coupled to Alexa Fluor® 488 dye. The EdU-
incorporated cells were then detected by flow cytometric analysis. We found that 
the percentage of S-phase cells decreased in a time- and dose-dependent manner, 






Figure 3.1.2. Garcinol inhibits cell proliferation of HNSCC cells. 
CAL27 (5×105/mL) were treated with 0, 15, and 25 μM of garcinol for 12, 24, 











3.1.3 Garcinol induces apoptosis in HNSCC cells. 
To investigate whether the inhibition of cell viability by garcinol is also 
due to its apoptotic effect, a variety of experiments were conducted in HNSCC 
cells.  
3.1.3.1 Garcinol increases the population of annexin V-positive cells. 
In the early stage of apoptosis, the membrane phospholipids as w ell as 
phosphatidylserines translocate rapidly from cytoplasmic interface and 
accumulate at extracellular surface (246). This process results in the loss of 
membrane asymmetry which can be detected using Annexin V. As a phospholipid 
binding protein, Annexin V preferentially binds to negatively charged 
phospholipids including phosphatidylserines (247). The Annexin V kit was 
utilized to monitor the progressing of early apoptosis in garcinol treated HNSCC 
cells according to their Annexin V and PI staining pattern. CAL27 and UMSCC1 
cells (5×105/mL) were exposed to 25 μM garcinol for different time points as 
indicated, and then were harvested, stained with PI and FITC-conjugated annexin 
V for flow cytometric analysis. Our data indicated that Annexin V-positive and 





Figure 3.1.3.1. Garcinol increases the population of annexin V-positive cells 
in HNSCC cells. 
A. CAL27 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 12, 24, and 48 
h, the cells were then harvested and stained with PI and annexin V, and analyzed 
by flow cytometry. Data representative of at least two independent experiments is 
shown. 
B. UMSCC1 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 12, 24, and 
48 h, the cells were then harvested and stained with PI and annexin V, and 
analyzed by flow cytometry. Data representative of at least two independent 






3.1.3.2 Garcinol increases the accumulation of HNSCC cells in Sub-G1 
phase. 
DNA fragmentation is a key feature associated with apoptosis, and the loss of 
DNA can be detected from ethanol permeabilized cells due to DNA fragmentation 
and presents as an accumulation of Sub-G1 population in flow cytometric analysis 
after PI staining (248). CAL27 and UMSCC1 cells (5×105/mL) were incubated 
with 25 μM garcinol for different time points as indicated, and then were 
collected and stained with PI, and analyzed for DNA contents by fluorescence-
activated cell sorting (FACS). We observed that garcinol could caused an 
increased accumulation of cells in Sub-G1 phase in a time-dependent manner in 





Figure 3.1.3.2. Garcinol increases the accumulation of HNSCC cells in Sub-
G1 phase. 
A. CAL27 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 12, 24, and 48 
h, then the cells were fixed by 70% ethanol, stained with PI, and subjected to 
FACS. Data representative of at least two independent experiments is shown. 
B. UMSCC1 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 12, 24, and 
48 h, then the cells were fixed by 70% ethanol, stained with PI, and subjected to 








3.1.3.3 Garcinol induces DNA fragmentation of HNSCC cells.  
The activation of endogenous endonucleases during apoptosis cleave 
double stranded DNA at the most accessible internucleosomal linker region, 
generating mono- and oligonucleosomes (249). The use of Cell Death Detection 
ELISAPLUS kit allows the specific determination of the enrichment of these 
degraded DNA fragments in the cytoplasm of cells. The cytoplasmic fraction of 
the cells was extracted after exposure of CAL27 cell to 25 μM garcinol for the 
indicated time intervals. The cytoplasmic lysates were subjected to the 
quantitative enzyme-immunoassay. The data revealed that garcinol significantly 
increased the DNA fragmentation level in a time-dependent manner in CAL27 
cells which is an indicative of apoptosis. 
 
Figure 3.1.3.3. Garcinol induces DNA fragmentation in HNSCC cells. 
CAL27 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 12, 24, and 48 h, 
after which the cytoplasmic fractions were collected and analyzed by Cell Death 
Detection ELISAPLUS kit to determine the degree of DNA. (*p <0.05) 
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3.1.3.4 Garcinol activates caspase-3 in HNSCC cells. 
Cysteine-aspartic acid protease 3 (caspase-3) is one of the key executioners 
of apoptosis, upon activation, it proteolytically cleaves many key proteins, such as 
the nuclear enzyme PARP, which are cleaved in many different systems during 
apoptosis (250). HNSCC cells were exposed to 25 μM garcinol for various time 
intervals, after which the whole cell lysates were examined by western for 
caspase-3 expression. It is clear from our data that garcinol induced caspase-3 
activation as evidenced by a time-dependent cleavage of caspase-3. It is also 
found that the activation of this effector caspase cleaved the full length PARP 
protein into smaller active fragment. These findings indicate that garcinol induces 






Figure 3.1.3.4. Garcinol activates caspase-3 in HNSCC cells. 
A. CAL27 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 3, 6, 12, and 
24 h; whole cell proteins were extracted and analyzed by western blot using 
antibodies specific to caspase-3 and PARP. β-actin as an internal control to verify 
equal loading of proteins was detected on the same membrane after stripping. 
Data representative of at least two independent experiments is shown. 
B. UMSCC1 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 3, 6, 12, 
and 24 h; whole cell proteins were extracted and analyzed by western blot using 
antibodies specific to caspase-3 and PARP. β-actin as an internal control to verify 
equal loading of proteins was detected on the same membrane after stripping. 
Data representative of at least two independent experiments is shown. 
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3.1.3.5 Garcinol activates both intrinsic and extrinsic caspase activation 
cascades to induce apoptosis in HNSCC cells. 
Current anti-cancer chemotherapies initiate a programmed cell death 
cascade engaging the activation of both intrinsic and extrinsic apoptosis signal 
transduction pathways in cancer cells (251). Western blot was used to explore the 
involvement of extrinsic and/ or intrinsic pathways in the garcinol-induced 
apoptosis. Whole cell lysates were extracted from HNSCC cells which were 
treated with 25 μM garcinol for 0, 3, 6, 12 , and 24 h, and were then subjected to 
western blot to analyze the expression of caspase-8 and caspase-9. A time-
dependent reduction of full length caspase-8 and caspase-9 were observed, with a 
corresponding increase in the expression level of cleaved caspase-8 and caspase-9, 
suggesting that garcinol-induced apoptosis in HNSCC cells is indeed mediated 




Figure 3.1.3.5. Garcinol causes the activation of both intrinsic and extrinsic 
caspase cascades in HNSCC cells. 
After treated with 25 μM garcinol for 0, 3, 6, 12, a nd 24 h, t he protein levels of 
caspase-8 and caspase-9 in whole cell lysates were examined by western blot. β-
actin as an internal control to verify equal loading of proteins was detected on the 
same membrane after stripping. Representative blots from at least two 






3.1.3.6 Garcinol modulates the expression of various proteins involved in 
the cell cycle progression in HNSCC cells. 
We next proceeded to investigate whether garcinol modulates the 
constitutive expression of various proteins involved in cell cycle progression. 
HNSCC cells were incubated with 25 μM garcinol for 0, 3, 6, 12, and 24 h, after 
which whole cell lysates were extracted. The expression of cyclin D1, cyclin E, 
and p27 were detected by w estern blot analysis. We found that garcinol 
downregulated the proteins involved in cell cycle progression namely cyclin D1 
and cyclin E, while upregulated the expression of p27, a negative regulator of cell 





Figure 3.1.3.6. Garcinol modulates the expression of various proteins 
involved in the cell cycle progression in HNSCC cells. 
A. CAL27 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 3, 6, 12, a nd 
24 h. Levels of cyclin D1, cyclin E, and p27 in whole cell lysates were analyzed 
by western blot. β-actin as an internal control to verify equal loading of proteins 
was detected on the same membrane after stripping. Representative blots from at 
least two independent experiments have been shown. 
B. UMSCC1 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 3, 6, 12,  
and 24 h. Levels of cyclin D1 and cyclin E in whole cell lysate were analyzed by 
western blot. β-actin as an internal control to verify equal loading of proteins was 
detected on the same membrane after stripping. Representative blots from at least 
two independent experiments have been shown. 
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3.1.3.7 Garcinol modulates the expression of various proteins involved in 
the survival/apoptosis of HNSCC cells. 
The susceptibility of tumor cells to apoptosis induced by anti-tumor drugs 
depends on t he balance between pro-apoptotic and survival (anti-apoptotic) 
signals (252). Next we investigated whether garcinol modulates the expression of 
pro-apoptotic and anti-apoptotic proteins that determine the ultimate fate of the 
tumor cells. HNSCC cells were exposed to 25 μM garcinol for different time 
intervals as indicated, whole cell lysates were then analyzed by western blot 
against proteins of interests. The results showed that garcinol downregulated the 
expression of several anti-apoptotic members of Bcl-2 family proteins namely 
Bcl-2, Bcl-xL and Mcl-1, as well as other inhibitors of apoptosis such as survivin, 
XIAP and c-FLIP. However, the expression of pro-apoptotic proteins namely 





Figure 3.1.3.7. Garcinol modulates the expression of various proteins 
involved in the survival/apoptosis of HNSCC cells. 
A. CAL27 (right panel) and UMSCC1 (left panel) cells (5×105/mL) were exposed 
to 25 μM garcinol for 0, 3, 6, 12, and 24 h; whole cell lysates were extracted and 
subjected to western blot against pro-apoptotic proteins. β-actin as an internal 
control to verify equal loading of proteins was detected on the same membrane 
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after stripping. Representative blots from at least two independent experiments 
have been shown. 
B. CAL27 (right panel) and UMSCC1 (left panel) cells (5×105/mL) were exposed 
to 25 μM garcinol for 0, 3, 6, 12, and 24 h; whole cell lysates were extracted and 
subjected to western blot against anti-apoptotic proteins. β-actin as an internal 
control to verify equal loading of proteins was detected on the same membrane 
after stripping. Representative blots from at least two independent experiments 














3.1.3.8 Garcinol donwregulates the transcription expression of various 
proteins involved in the cell proliferation and survival of HNSCC 
cells. 
To determine whether garcinol also modulates the transcription of various 
cell cycle and survival genes, the mRNA expression levels of cyclin D1, Bcl-xL, 
Mcl-1, Bcl-2, and survivin were measured upon garcinol treatment. CAL27 and 
UMSCC1 cells were exposed to 25 µM garcinol for various time points as 
indicated, and RNA was extracted and subjected to real time PCR. We first 
noticed the constitutive mRNA expression of various oncogenic genes in HNSCC 
cells, and garcinol significantly inhibited the expression of these genes at 




Figure 3.1.3.8. Garcinol donwregulates the transcription expression of 
various proteins involved in the cell proliferation and survival of HNSCC 
cells. 
A. CAL27 cells (1×106/mL) were exposed to 25 µM garcinol for 0, 2, 4, 6, and 8 
h. The cells were then harvested for RNA extraction, after which the relative 
expression of mRNA was evaluated by real time PCR. (*p <0.05) 
B. UMSCC1 cells (1×106/mL) were exposed to 25 µM garcinol for 0, 2, 4, and 6 
h. The cells were then harvested for RNA extraction, after which the relative 
expression of mRNA was evaluated by real time PCR. (*p <0.05) 
83 
 
3.1.4 Garcinol downregulates the expression of gene product involved in 
angiogenesis in HNSCC cells. 
VEGF is the main angiogenic factor that is commonly overexpressed in 
variety of cancers including HNSCC (253, 254). To examine the effects of 
garcinol on VEGF, HNSCC cells were treated with 25 µM garcinol for various 
time points. Thereafter, protein levels of VEGF were detected by western blot 
analysis, while mRNA expression of VEGF was analyzed by real time PCR. The 
results showed that garcinol not only downregulated the protein expression of 
VEGF, but also suppressed VEGF gene at transcription level in a time-dependent 






Figure 3.1.4. Garcinol downregulates the expression of VEGF in HNSCC 
cells. 
A. CAL27 (upper panel) and UMSCC1 (lower panel) cells (5×105/mL) were 
exposed to 25 μM garcinol for 0, 3, 6, 12, and 24h. Levels of VEGF in whole cell 
lysates were analyzed by western blot. β-actin as an internal control to verify 
equal loading of proteins was detected on the same membrane after stripping. 
Representative blots from at least two independent experiments have been shown. 
B. CAL27 cells (1×106/mL) were exposed to 25 μM garcinol for 0, 2, 4, 6, and 8h. 
The cells were then harvested for RNA extraction, after which the relative 
expression of mRNA was evaluated by real time PCR. (*p <0.05) 
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3.1.5 Garcinol significantly abrogates HNSCC cell migration and invasion. 
The ability of cancer cells to undergo migration and invasion allow them 
to disseminate into the circulation, and promote metastatic progression into the 
distant organs (255, 256). To assess the anti-migratory and anti-invasive potential 
of garcinol, we examined its effects on the chemotactic motility of HNSCC cells 
using the wound-healing migration and invasion assays. 
3.1.5.1 Garcinol suppresses CXCL12-induced HNSCC cell migration. 
The wound-healing assay was performed using IBIDI µ-Dish which 
created a gap of 500 µm by the IBIDI culture insert. CAL27 cells seeded in the 
petri dish were treated with 15 µM garcinol for 8 h before exposed to chemokine 
CXCL12 (100 ng/mL) for 24 h, and the gap differences were compared at the 
time of 24 h incubation. We noticed that CXCL12 accelerated the “wound-healing” 
process, and the wound closing in cells treated with garcinol was much less as 





Figure 3.1.5.1. Garcinol significantly inhibits migratory ability of HNSCC 
cells. 
Confluent monolayers of CAL27 cells with a 500 µ m gap created by IBIDI 
culture insert were treated with 15 µM garcinol in the presence or absence of 
CXCL12. Upper panel, representative images showed the same area at time zero 
and after 24 h of incubation. Lower panel, width of wound was measured at time 
zero and 24 h of incubation with and without garcinol treatment, and the graph 
was plotted against the percentage of migration distance the cells moved before 




3.1.5.2 Garcinol significantly blocks the invasive ability of HNSCC cells. 
The invasive capability of HNSCCcells after garcinol treatment was 
examined using matrigel invasion assay. CAL27 cells plated in the matrigel 
chamber were pre-treated with 15 μM garcinol for 8 h, after which 100 ng/ mL 
CXCL12 was added into the lower chamber of the 24-well plate for additional 24 
h incubation. After the incubation, the cells invaded the matrigel to move towards 
the chemoattractant contacting outer layer. Invaded HNSCC cells were stained 
with crystal violet solution and analyzed under bright field microscopy. It was 
clearly evident from our in vitro invasion assay that garcinol inhibited the 






Figure 3.1.5.2. Garcinol inhibits invasive potential of HNSCC cells. 
Upper panel, CAL27 cells (5×105 cells) were plated in the upper compartment of 
the transwell chamber, and then were treated with 15 µM garcinol in the presence 
or absence of CXCL12 (100 ng/mL). The chambers were then subjected to crystal 
violet staining to assess for cellular invasion. Representative images of at least 
two independent experiments are shown. Lower panel, the number of the invaded 





3.1.5.3 Garcinol donwnregulates the expression of proteins involved in 
HNSCC cell migration and invasion. 
Western blot was performed to explore the effects of garcinol on key 
proteins regulating cell adhesion, migration and invasion processes. CAL27 cells 
were exposed to 25 μM garcinol for various time points as indicated, and whole 
cell lysates were analyzed for the expression of proteins of interest. We found that 
garcinol treatment indeed downregulated the expression of MMP-9, MMP-2, 
ICAM-1, and CXCR4 in a time-dependent manner in HNSCC cells. 
 
Figure 3.1.5.3. Garcinol donwnregulates the expression of proteins involved 
in HNSCC cell migration and invasion. 
CAL27 cells (5×105/mL) were exposed to 25 μM garcinol for 0, 3, 6, 12, and 24 h. 
Levels of MMP-9, MMP-2, ICAM-1, and CXCR4 in whole cell lysates were 
analyzed by western blot. β-actin as an internal control to verify equal loading of 
proteins was detected on the same membrane after stripping. Representative blots 
from at least two independent experiments have been shown. 
90 
 
3.2 Effects of garcinol on STAT3 signaling cascade in HNSCC cells 
3.2.1 HNSCC cells express constitutively active STAT3 protein. 
To analyze the STAT3 activation profile in human HNSCC, panel of 
HNSCC cell lines were screened by western blot to detect the expression of 
phospho-STAT3 (p-STAT3) and the basal level of total STAT3. (Hereafter in this 
thesis, p-STAT3 indicates tyrosine phosphorylation of STAT3 at 705 residue 
unless stated otherwise). Whole cell extracts of CAL27, UMSCC1, MDA686LN, 
MDA686Tu and Tu138, and were prepared and used for the detection of p-
STAT3 (Tyr-705) and total STAT3 expression. We found that majority of the 
HNSCC cell lines including CAL27, UMSCC1, Tu138 and MDA686Tu 
expressed substantial level of constitutively phosphorylated STAT3, while 





Figure 3.2.1. Basal level of p-STAT3 and STAT3 expression in HNSCC cell 
lines. 
Whole cell lysates of different human HNSCC cell lines CAL27, UMSCC1, 
MDA686LN, MDA686Tu and Tu138 were extracted and subjected to western 
blot using antibodies against p-STAT3 and total STAT3. β-actin as an internal 
control to verify equal loading of proteins was detected on the same membrane 











3.2.2 IL-6 induces STAT3 phosphorylation in HNSCC cells. 
The phosphorylation of STAT3 is known to be induced by various cytokines 
and growth factors such as I L-6 (70). We then tested if IL-6 stimulation could 
induce the phosphorylation of STAT3 in the HNSCC cell lines which do not  
display constitutive activated STAT3. To confirm this, one set of MDA686Tu 
cells were treated with fixed concentration of IL-6 for indicated time intervals, 
while the other set of cells were treated with different concentration of IL-6 for 
one specific time point. The STAT3 phosphorylation levels were then detected by 
western blot. It is clear from our results that IL-6 treatment induced substantial 








Figure 3.2.2. IL-6 stimulates STAT3 activation in HNSCC cells. 
A. Western blot analysis of p-STAT3 in MDA686Tu cells (5×105/mL) treated 
with 0, 5, 1 0, 25, and 50 ng/mL of IL-6 for 30 min. STAT3 was detected on the 
same membrane after stripping to verify equal loading of proteins. Data 
representative of at least two independent experiments is shown. 
B. Western blot analysis of p-STAT3 in MDA686Tu cells (5×105/mL) treated 
treated with 25 ng/ mL of IL-6 for 0, 15, 30,  60, a nd 120 min. STAT3 was 
detected on the same membrane after stripping to verify equal loading of proteins. 





3.2.3 Garcinol suppresses the constitutive STAT3 phosphorylation in 
HNSCC cells. 
Constitutive activation of STAT3 is frequently encountered in HNSCC cells 
and STAT3 inhibition can be considered as an important therapeutic option for 
the patients (83). To determine whether garcinol modulates STAT3 activation, 
HNSCC cells were exposed to various concentrations of garcinol for different 
time intervals as indicated, and then the extracted whole cell lysates were 
subjected to western blot to detect the STAT3 phosphorylation. The results 
showed that garcinol downregulated the constitutive STAT3 phosphorylation in a 




Figure 3.2.3. Garcinol suppresses the constitutive phosphorylation of STAT3 
in HNSCC cells. 
A. Western blot analysis of p-STAT3 in CAL27 cells (5×105/mL) treated with 
different concentrations of garcinol for 120 m in. STAT3 was detected on the 
same membrane after stripping to verify equal loading of proteins. Representative 
blots from at least two independent experiments have been shown. 
B. Western blot analysis of p-STAT3 in CAL27 cells (5×105/mL) treated with 50 
µM garcinol for 0, 15, 30, 60, a nd 120 min. STAT3 was detected on the same 
membrane after stripping to verify equal loading of proteins. Representative blots 




3.2.4 Garcinol does not affect serine phosphorylation of STAT3 in HNSCC 
cells. 
Phosphorylation of a serine residue (serine 727) in the transcriptional 
activation domain of STAT3 enhances its transcriptional activity (257). Therefore, 
we examined whether garcinol could modulate the serine phosphorylation of 
STAT3 as well under the same experimental settings. Serine phosphorylation of 
STAT3 in CAL27 cells upon ga rcinol treatment was detected by w estern blot 
using antibody specific to STAT3 serine 727 residue. Interestingly, garcinol was 
found to have no significance influence on serine phosphorylation of STAT3, 
thereby indicating its specificity towards inhibition of p-STAT3 (Tyr 705) residue.  
 
Figure 3.2.4. Garcinol did not affect serine phosphorylation of STAT3 in 
HNSCC cells. 
Western blot analysis of p-STAT3 (Ser 727) in CAL27 cells (5×105/mL) treated 
with 50 µM garcinol for 0, 15, 30, 60, a nd 120 min. STAT3 was detected on the 
same membrane after stripping to verify equal loading of proteins. Data 
representative of at least two independent experiments is shown. 
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3.2.5 Garcinol abrogates IL-6-induced phosphorylation of STAT3 in 
HNSCC cells.  
As observed in the above experiments, MDA686Tu exhibited elevated level 
of STAT3 phosphorylation upon IL-6 treatment. To analyze the potential 
inhibiting capability of garcinol on IL-6-induced STAT3 phosphorylation, 
western blot analysis was done. MDA686Tu cells were pretreated with 25 µM 
garcinol for 0, 1, 2, 4, and 6 h and then incubated with 25 ng/mL of IL-6 for 30 
min. Thereafter, phosphorylation level of STAT3 was determined by western blot. 
Comparable to its inhibitory effects on constitutively active STAT3, garcinol also 
suppressed the IL-6-induced STAT3 phosphorylation in a time-dependent manner 
in MDA686Tu cells.  
 
Figure 3.2.5. Garcinol inhibits IL-6-induced phosphorylation of STAT3 in 
HNSCC cells. 
MDA686Tu cells (5×105/mL) were pretreated with 25 µM garcinol for different 
time points as indicated, and then incubated with 25 ng/mL of IL-6 for 30 min. 
Phosphorylation of STAT3 in whole cell lysates was assessed by w estern blot 
analysis using antibody against p-STAT3. STAT3 was detected on the same 
membrane after stripping to verify equal loading of proteins. Representative blots 
from at least two independent experiments have been shown. 
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3.2.6 Garcinol depletes nuclear pool of STAT3 in HNSCC cells. 
Following tyrosine phosphorylation and dimerization, STAT3 dimers 
translocate to the nucleus and regulate transcriptional activation (70). Since 
nuclear translocation is essential for the function of STAT3, we next investigated 
the effect of garcinol on nuclear translocation of STAT3. HNSCC cells were 
exposed to 50 µM garcinol for 120 min on chamber slides, after which the slides 
were analyzed for the intracellular distribution of STAT3 by 
immunocytochemistry. The obtained results showed that STAT3 localized in both 
cytoplasm and nuclei in vehicle control, while this protein predominantly resided 
in cytoplasm in the garcinol treated cells. Nuclear extracts from garcinol-treated 
HNSCC cells were further analyzed by western blot and showed a d ecrease in 
nuclear p65 protein level. Together with the immunocytochemistry study, our 
results suggest that garcinol blocked the nuclear translocation of STAT3 molecule 




Figure 3.2.6. Garcinol inhibits the nuclear translocation of STAT3 in 
HNSCC cells. 
A. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 120 min, and 
then processed and analyzed by immunocytochemistry. Representative images of 
at least two independent experiments are shown. 
B. The protein levels of p-STAT3 and total STAT3 in nuclear extracts from 
garcinol treated CAL27 cells were determined by western blot analysis. Lamin B1 
was detected on the same membrane after stripping to verify equal loading of 




3.2.7 Garcinol abrogates DNA-binding ability of STAT3 in HNSCC cells. 
After translocating to the nucleus, STAT3 recognizes and binds to specific 
DNA elements to activate transcription (76), thus we aimed to determine whether 
garcinol inhibits the DNA-binding ability of STAT3. Nuclear proteins extracted 
from vehicle-and garcinol-treated CAL27 cells were analyzed by E LISA-based 
Trans AM™ STAT3 assay kit. Our result confirmed that garcinol significantly 





Figure 3.2.7. Garcinol abrogates DNA-binding ability of STAT3 in HNSCC 
cells. 
A. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 0, 15, 30, 60, 
and 120 min; nuclear extracts were analyzed by DNA-binding assay. (*p <0.05) 
B. CAL27 cells (5×105/mL) were treated with 0, 5, 10, 25, a nd 50 µM garcinol 




3.2.8 Garcinol blocks STAT3 dependent reporter gene expression in 
HNSCC cells. 
Since garcinol has been found to inhibit the STAT3 DNA-binding activity as 
shown in the previous experiments, we next examined whether garcinol affects 
STAT3-dependent gene transcription. When the STAT3-luciferase (STAT3-Luc) 
plasmid transfected HNSCC cells were incubated with IL-6 or EGF, the luciferase 
activity was found to be increased; and the IL-6-induced or EGF-induced 
luciferase activities were suppressed in a dose-dependent manner in the presence 
of garcinol. These results indicated that garcinol abrogates STAT3-dependent 






Figure 3.2.8. Garcinol inhibits IL-6 and EGF induced STAT3 dependent 
reporter gene expression.  
A. Transiently transfected MDA686Tu cells (1×104/mL) were exposed to 
different concentrations of garcinol as indicated for 6 h, followed by addition of 
IL-6 (25 ng/mL) for 6 h. Luciferase activity was determined using Bright-Glo™ 
Luciferase Assay System. (*p <0.05) 
B. Transiently transfected MDA686Tu cells (1×104/mL) were exposed to 
different concentrations of garcinol as indicated for 6 h, followed by addition of 
EGF (100 ng/mL) for 6 h. Luciferase activity was determined using Bright-Glo™ 
Luciferase Assay System. (*p <0.05) 
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3.2.9 Garcinol suppresses the constitutive activation of Src and JAK family 
kinases in HNSCC cells. 
STAT3 activation is known to be regulated by Janus-activated kinase family 
and soluble tyrosine kinases Src (70). Thus, to determine whether the suppression 
of STAT3 activation upon garcinol treatment resulted from suppression of 
upstream kinases, we conducted western blot to examine the phosphorylation of 
Src, JAK1, and JAK2 in garcinol treated HNSCC cells. We noticed that garcinol 
inhibited the constitutive phosphorylation of Src in a time-dependent manner. 
Similarly, constitutively activated JAK1 and JAK2 were inhibited substantially by 




Figure 3.2.9. Garcinol suppresses the constitutive activation of Src and JAK 
family kinases in HNSCC cells. 
A. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 0, 15, 30, 60, 
and 120 min. Phosphorylation of Src in whole cell lysates was assessed by 
western blot using p-Src antibody. Src was detected on the same membrane after 
stripping to verify equal loading of proteins. Representative blots of at least two 
independent experiments have been shown. 
B. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 0, 15, 30, 60,  
and 120 m in. Phosphorylation of JAK1 in whole cell lysates was assessed by 
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western blot using p-JAK1 antibody. JAK1 was detected on the same membrane 
after stripping to verify equal loading of proteins. Representative blots of at least 
two independent experiments have been shown. 
C. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 0, 15, 30, 60,  
and 120 m in. Phosphorylation of JAK2 in whole cell lysates was assessed by 
western blot using p-JAK2 antibody. JAK2 was detected on the same membrane 
after stripping to verify equal loading of proteins. Representative blots of at least 














3.2.10 Garcinol attenuates the IL-6-induced phosphorylation of Janus 
kinases in HNSCC cells. 
The IL-6 stimulation leads to the activation of JAK family kinases which 
subsequently phosphorylate STAT3 (71). We next determined if garcinol inhibits 
STAT3 phosphorylation by modulating the activation of upstream JAK kinases. 
To analyze this aspect, MDA686Tu cells were first incubated with 25 µM 
garcinol for the indicated time points, after which the IL-6 treatment was applied. 
Our experimental findings indicated that IL-6 stimulated the phosphorylation of 
JAK1 and JAK2, and the IL-6-induced phosphorylation of both kinases was 




Figure 3.2.10. Garcinol inhibits IL-6-induced phosphorylation of JAK1 and 
JAK2 in HNSCC cells. 
A.MDA686Tu cells (5×105/mL) were pretreated with 25 µM garcinol for 0, 1, 2,  
4, and 6 h, and then incubated with 25 ng/mL of IL-6 for 30 min. Phosphorylation 
of JAK1 in whole cell lysates was assessed by western blot using antibody against 
p-JAK1. JAK1 was detected on the same membrane after stripping to verify equal 
loading of proteins. Representative blots of at least two independent experiments 
have been shown. 
B.MDA686Tu cells (5×105/mL) were pretreated with 25 µM garcinol for 0, 1, 2, 
4, and 6 h, and then incubated with 25 ng/mL of IL-6 for 30 min. Phosphorylation 
of JAK2 in whole cell lysates was assessed by western blot using antibody against 
p-JAK2. JAK2 was detected on the same membrane after stripping to verify equal 
loading of proteins. Representative blots of at least two independent experiments 
have been shown. 
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3.2.11 Tyrosine phosphatases may be involved in STAT3 inhibitory effects of 
garcinol in HNSCC cells.  
Because STAT3 activation is also negatively regulated by several negative 
regulators such as protein tyrosine phosphatases (PTPs) (73, 258), we next 
examined whether the inhibition of STAT3 phosphorylation by garcinol could be 
due to the activation of PTPs. CAL27 cells were treated with the 50 µM garcinol 
and various concentrations of the broad spectrum tyrosine phosphatase inhibitor 
sodium pervanadate for 120 min, and the whole cell proteins were analyzed by 
western blot for the detection of p-STAT3. We found that sodium pervanadate 
reversed the garcinol-mediated inactivation of STAT3 in a dose-dependent 
manner.  
 
Figure 3.2.11. Sodium pervanadate blocked the inhibition of STAT3 
phosphorylation induced by garcinol. 
CAL27 cells (5×105/mL) were exposed to 0, 1, 5, 10, a nd 25 µ M sodium 
pervanadate and 50 µ M garcinol for 120 min. Phosphorylation of STAT3 in 
whole cell lysates was assessed by western blot using antibody against p-STAT3. 
STAT3 was detected on the same membrane after stripping to verify equal 




3.2.12 Garcinol does not affect the activation/expression of protein tyrosine 
phosphatases (PTPs). 
A number of PTPs have been implicated in the regulation of STAT3 
signaling cascade (258). Thus, we examined whether garcinol modulate the 
cytoplasmic PTPs including Src homology 2 domain-containing protein tyrosine 
phosphatase 1 (SHP1), SHP2, PTP1B, and PTEN. CAL27 cells were exposed to 
50 µM garcinol for various time intervals, and then western blot assay was done 
to detect the expression of SHP1, SHP2, PTP1B, and PTEN. The phosphorylation 
levels of SHP1 was also analyzed using phospho-specific SHP1 (S591and Y536) 
antibodies. Interestingly, we noted that garcinol treatment did not change the 




Figure 3.2.12. Garcinol does not affect the expression and/or activation of 
protein tyrosine phosphatases in HNSCC cells. 
After incubation of 50 µM garcinol for 0, 15, 30, 60, a nd 120 min, the protein 
levels of SHP1, SHP2, PTP1B, PTEN, and p-SHP1 (S591and Y536) in whole cell 
lysates were determined by western blot. β-actin as an internal control to verify 
equal loading of proteins was detected on the same membrane after stripping. 
Representative blots of at least two independent experiments have been shown. 
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3.3 Effects of garcinol on NF-κB signaling pathway in HNSCC cells 
3.3.1 HNSCC cells express constitutively activated NF-κB. 
Several prior studies have documented the prevalence of constitutive 
activated NF-κB in HNSCC cell lines and tumor tissues specimens (119-122). 
Thus, various HNSCC cell lines including CAL27, UMSCC1, MDA686LN, 
MDA686Tu, and Tu138 were examined for the NF-κB activation levels. Nuclear 
extracts of the above mentioned cell lines were prepared and analyzed by western 
blot for the expression of phospho-NF-κB (p-p65) and NF-κB (p65). We observed 
that CAL27 and UMSCC1 cell lines exhibit constitutively activated NF-κB levels, 
while the expression of active p65 in MDA686LN is moderate. On the contrary, 





Figure 3.3.1. NF-κB (p65) activation profile in HNSCC cells. 
Nuclear proteins of human HNSCC cells including CAL27, UMSCC1, 
MDA686LN, MDA686Tu, and Tu138 were extracted, and subjected to western 
blot using p-p65 and p65 specific antibodies. Lamin B1 was detected on the same 
membrane after stripping to verify equal loading of proteins. Representative 









3.3.2 Garcinol suppresses the constitutive NF-κB activation in HNSCC cells. 
The constitutively activated NF-κB signaling in head and neck cancers has 
been reported to mediate resistance to apoptosis (124, 125); thus, we aimed to 
examine the effect of garcinol on the constitutive activation of NF-κB in HNSCC 
cells. HNSCC cells were exposed to fixed concentrations of garcinol for various 
time intervals as indicated. Nuclear lysates were extracted and subjected to 
western blot to detect p-p65 and p65 levels. It is evident from our experimental 
findings that garcinol suppressed the constitutive NF-κB phosphorylation in 
CAL27 in a time-dependent manner, and similar effects were observed in 




Figure 3.3.2. Garcinol suppresses the constitutive p65 phosphorylation and 
activation. 
A. CAL27 cells (1×106/mL) were exposed to 50 µM garcinol for 0, 1, 2, 4, and 6 
h, and then the nuclear protein levels of p-p65 and total p65 were detected by 
western blot. Lamin B1 was detected on the same membrane after stripping 
to verify equal loading of proteins. Representative blots from at least two 
independent experiments have been shown. 
B. UMSCC1 cells (1×106/mL) were exposed to 25 µM garcinol for 0, 1, 2, 4, and 
6 h, and then the nuclear protein levels of p-p65 and total p65 were detected by 
western blot. Lamin B1 was detected on the same membrane after stripping 
to verify equal loading of proteins. Representative blots from at least two 
independent experiments have been shown. 
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3.3.3 Garcinol abrogates phosphorylation and degradation of the 
constitutive IκBα in HNSCC cells. 
As described in the Introduction section, NF-κB signaling is activated when 
NF-κB complex translocates to nucleus to regulate the transcription. The 
liberation of p65/p50 heterodimer requires the phosphorylation of IκBα which 
results in the proteasomal degradation of this NF-κB inhibitor (93). To study the 
involvement of this process in garcinol-induced inhibition of NF-κB activation, 
cytoplasmic fraction of garcinol treated HNSCC cells were extracted and 
analyzed for the p-IκBα and IκBα expression levels. We found that garcinol 
inhibited the phosphorylation of constitutive IκBα in a time-dependent manner, 





Figure 3.3.3. Garcinol inhibits the constitutive phosphorylation of IκBα in 
HNSCC cells. 
A. CAL27 cells (1×106/mL) were exposed to 50 µM garcinol for 0, 1, 2, 4, and 6 
h. Cytoplasmic proteins were prepared and subjected to western blot using p-IκBα 
and total IκBα antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as an internal control to verify equal loading of proteins was detected on the same 
membranes after stripping. Representative blots from at least two independent 
experiments have been shown. 
B. UMSCC1 cells (1×106/mL) were exposed to 25 µM garcinol for 0, 1, 2, 4, and 
6 h. Cytoplasmic proteins were prepared and subjected to western blot using p-
IκBα and total IκBα antibodies. GAPDH as an internal control to verify equal 
loading of proteins was detected on the same membrane after stripping. 
Representative blots from at least two independent experiments have been shown. 
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3.3.4 Garcinol reduces NF-κB DNA-binding activity in HNSCC cells. 
To further evaluate the negative effect of garcinol on the constitutive NF-κB 
activation, garcinol-treated CAL27 and UMSCC1 cells were tested by ELISA-
based DNA-binding assay. HNSCC cells were exposed for 6 h  to the various 
concentrations of garcinol as indicated, and then collected for nuclear proteins 
extraction. Analysis of nuclear lysates extracted from both CAL27 and UMSCC1 
cells using Trans AM™ NF-κB assay kit showed that garcinol significantly 





Figure 3.3.4. Garcinol inhibits NF-κB DNA-binding activity in HNSCC cells.  
A. CAL27 cells (1×106/mL) were exposed for 6 h t o 0, 10, 25, a nd 50 µM 
garcinol; nuclear extracts were analyzed by DNA-binding assay. (*p <0.05) 
B. UMSCC1 cells (1×106/mL) were exposed for 6 h t o 0, 5, 10, 15, a nd 25 µM 





3.3.5 Garcinol inhibits the constitutive activation of TAK1 and IKKα/β in 
HNSCC cells. 
The degradation of negative regulator of NF-κB, IκBα protein, is modulated 
through IKK-dependent phosphorylation (93). We next determined if garcinol 
inhibits NF-κB by modulating the activation of upstream kinases TAK1 and IKK. 
Whole cell lysates were extracted from garcinol treated HNSCC cells, and 
subjected to western blot against p-TAK1, and p-IKKα/β specific antibodies. Our 
experimental results showed that garcinol substantially suppressed the 









Figure 3.3.5. Garcinol inhibits the activation of upstream kinases involved in 
the NF-κB signaling in HNSCC cells.  
A. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 0, 30, 60, 120 , 
and 240 min; whole cell lysates were extracted and subjected to western blot 
using p-TAK1 antibody. TAK1 was detected on the same membrane after 
stripping to verify equal loading of proteins. Representative blots from at least 
two independent experiments have been shown. 
B. CAL27 cells (5×105/mL) were exposed to 50 µM garcinol for 0, 30, 60, 120,  
and 240 m in; whole cell lysates were extracted and subjected to western blot 
using p-IKKα/β antibody. IKKα was detected on the same membrane after 
stripping to verify equal loading of proteins. Representative blots from of at least 
two independent experiments have been shown. 
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3.4 Potential effect of garcinol on the Akt signaling pathway in HNSCC 
cells 
3.4.1 Garcinol suppresses constitutive Akt/mTOR/p70S6K activation in 
HNSCC cells. 
Akt/mTOR/S6K1 is one of the major anti-apoptotic pathways that can confer 
the survival advantage and also mediate the resistance of HNSCC cells against 
various chemotherapeutic agents (259, 260). We therefore investigated whether 
garcinol can downregulate the constitutive Akt/mTOR/S6K1 activation in 
HNSCC cells. As shown in our results, constitutive activation of the 
serine/threonine protein kinase Akt was inhibited by garcinol in a time-dependent 
manner. In addition, the constitutive mTOR and S6K1 activation was also 
suppressed substantially upon garcinol treatment in HNSCC cells. These results 
indicate that garcinol exerts the anticancer effects through the negative regulation 




Figure 3.4.1. Garcinol inhibits Akt/mTOR/p70S6K axis in HNSCC cells.  
A. Whole cell extracts from CAL27 cells (5×105/mL) treated 50 µM garcinol for 
0, 15, 30, 6 0, and 120 min were analyzed by western blot using p-Akt antibody. 
Akt was detected on the same membrane after stripping to verify equal loading of 
proteins. Representative blots from at least two independent experiments have 
been shown. 
B. Whole cell extracts from CAL27 cells (5×105/mL) treated 50 µM garcinol for 
0, 15, 30, 60, and 120 min were analyzed by western blot using p-mTOR antibody. 
mTOR was detected on the same membrane after stripping to verify equal 
loading of proteins. Representative blots from at least two independent 
experiments have been shown. 
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C. Whole cell extracts from CAL27 cells (5×105/mL) treated 50 µM garcinol for 
0, 15, 30, 60, a nd 120 m in were analyzed by western blot using p-p70S6K 
antibody. p70S6K was detected on the same membrane after stripping to verify 
equal loading of proteins. Representative blots from at least two independent 
















3.4.2 Garcinol abrogates the IL-6-induced phosphorylation of Akt in 
HNSCC cells. 
Activated Akt has been shown to play a cr itical role in the mechanism of 
action of IL-6 (261). We also examined whether the effect of garcinol on IL-6-
induced Akt activation. MDA686Tu cells were first incubated with 25 µM 
garcinol for the indicated time points, after which the IL-6 treatment was applied. 
Our experimental findings indicated that IL-6 stimulated the phosphorylation of 
Akt, and pretreatment with garcinol suppressed the Akt phosphorylation in a time-
dependent manner.  
 
Figure 3.4.2. Garcinol inhibits IL-6-induced phosphorylation of AKT in 
HNSCC cells.  
MDA686Tu cells (5×105/mL) were pretreated with 25 µM garcinol for 0, 1, 2, 4, 
and 6 h, and then incubated with 25 ng/mL of IL-6 for 30 min. Whole cell lysates 
were extracted and subjected to western blot using antibodies against p-AKT. 
AKT was detected on the same membrane after stripping to verify equal 
loading of proteins. Representative blots from at least two independent 




3.5 Garcinol exerts significant growth inhibitory effects in HNSCC 
xenograft mouse model. 
3.5.1 Pharmacokinetic properties of garcinol 
In order to examine the efficacy of garcinol in a xenograft mouse model, a 
pharmacokinetic study of garcinol was conducted to define suitable doses for 
treatment of mice in pharmacodynamics study. Two doses of garcinol (0.5 and 2 
mg/kg) were used for evaluation of pharmacokinetic property of garcinol through 
intraperitoneal administration. Blood was collected at 10 min, 30 min, 1, 2, 4, 6  
and 8 h post dose, after which the processed serum samples were subjected to LC-
MS/MS. After i.p. administration, garcinol was quickly absorbed into the 
bloodstream and reached a peak serum concentration (Cmax) of 1825.4 and 
6635.7 nM at 0.5 h pos t dose for dose of 0.5 and 2 mg/kg, respectively. In 
addition, the area under the serum concentration-time curve (AUC) at 8 h is 




Figure 3.5.1. Pharmacokinetic studies with garcinol. 
Athymic nu/nu female mice were dosed with 0.5 mg/kg and 2 mg/kg of garcinol, 
the serum concentrations of the drug were assessed at 10 min, 30 min, 1 h, 2 h, 4  
h, 6 h, a nd 8 h pos t dose. Each point represents a m ean value of three serum 
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3.5.2 Garcinol inhibits the growth of human HNSCC xenograft tumors. 
Based on t he aforementioned results, we next analyzed whether garcinol 
suppresses the growth of HNSCC xenograft in athymic nu/nu mice. To establish 
the human HNSCC xenograft mouse model, CAL27 cells were subcutaneously 
injected in the right flank of athymic nu/nu male mice for the tumors to develop. 
The tumor bearing mice were then randomized into three groups and received 
control or garcinol treatment up to four weeks following the experimental 
protocol. Tumor diameters and body weight were measured twice a week. We 
noticed that the tumors in the control mice grew rapidly compared to garcinol 
treated groups. From the third week onwards, mice receiving garcinol treatment 
were observed to have lower tumor volumes compared with the control group, 






Figure 3.5.2. Garcinol inhibits the growth of human HNSCC xenograft 
tumors. 
A. Schematic representation of experimental protocol described in “Materials and 
Methods”. Group I was given 0.1% DMSO alone, group II was given garcinol (1 
mg/kg body weight), and group III was given garcinol (2 mg/kg body weight). 
B. The diameters of the tumor were measured twice per week, after which the 





3.5.3 Garcinol inhibits the constitutive STAT3 and NF-κB activation in 
HNSCC tumor tissues. 
Our data obtained from in vitro experiments has demonstrated that 
garcinol significantly inhibited the STAT3 and NF-κB activation in HNSCC cell 
lines. To determine whether garcinol also modulates these signaling cascades to 
elicit its anti-cancer effects in vivo, tumor tissues from xenograft mice were 
studied by immunohistochemistry analysis. At the end of the four week therapy, 
animals were sacrificed; thereafter the tumor tissues were excised from all the 
groups and processed by immunohistochemistry. We observed that garcinol 
significantly inhibited the constitutive STAT3 activation and p65 expression in 




Figure 3.5.3. Garcinol donwregulates p-STAT3 and p65 expression in vivo in 
HNSCC xenograft mouse model. 
A. Tumor tissues obtained were subjected to immunohistochemistry using p-
STAT3 specific antibody. Representative image for each group is shown above.  
B. Tumor tissues obtained were subjected to immunohistochemistry using p65 







3.5.4 Garcinol inhibits Ki-67 and CD31 expression in HNSCC tumor tissues. 
Since Ki-67 is used as a cellular marker for proliferation (262) and CD31 
index is a biomarker for microvessel density (263), we next determined to 
whether garcinol can modulate these biomarkers to manifest its observed 
anticancer effects against HNSCC. To explore this possibility, 
immunohistochemistry assay was performed using tumor tissues excised from the 
xenograft mice. Our experimental findings showed that garcinol downregulated 
the expression of both Ki-67 and CD31 in tumor tissues, suggesting it’s anti-





Figure 3.5.4. Garcinol inhibits Ki-67 and CD31 expression in HNSCC tumor 
tissues. 
A. Tumor tissues obtained were subjected to immunohistochemistry using Ki-67 
antibody. Representative image for each group is shown above. 
B. Tumor tissues obtained were subjected to immunohistochemistry using CD31 





3.6 Garcinol sensitizes human HNSCC to cisplatin exposure in a xenograft 
mouse model. 
Platinum compounds such as cisplatin and carboplatin are used as the first-
line chemotherapy for the treatment of HNSCC (138, 139). However, they often 
lead to undesiable results due to the commonly encountered problems related to 
chemoresistance and toxicity (148, 150). Therefore, we also evaluated the 
potential of garcinol to sensitize HNSCC to cisplatin treatment both in cell lines 
and in a xenograft mouse model.  
 
3.6.1 Garcinol suppresses the cisplatin-induced NF-κB activation in 
HNSCC cells. 
3.6.1.1 Cisplatin induces NF-κB activation in HNSCC cells. 
It has been reported that several chemotherapeutic agents including cisplatin 
induce the activation of NF-κB signaling to confer chemoresistance in several 
malignancies including HNSCC (115, 264, 265). To confirm these findings, 
MDA686LN cells were exposed to different concentrations of cisplatin, after 
which the nuclear proteins were extracted and analyzed by western blot and NF-
κB DNA-binding assays. Interestingly, the western blot results showed that 
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cisplatin indeed induced the level of activated p65 in a dose- dependent manner. 
This observation was further confirmed by t he elevated level of NF-κB DNA-
binding activity in cisplatin treated cells.  
 
Figure 3.6.1.1. Cisplatin induces NF-κB activation.  
A. MDA686LN cells (1×106/mL) were incubated with 0, 5, 10, 15, and 25 µM 
cisplatin for 12 h, and then the nuclear protein levels of p-p65 and total p65 were 
detected by western blot. Membrane was stripped and reprobed for lamin B1 to 
confirm equal loading. Data representative of at least two independent 
experiments is shown. 
B. MDA686LN cells (1×106/mL) were incubated with 0, 5, 10, 15, a nd 25 µM 
cisplatin for 12 h, a nd nuclear lysates were extracted and subjected to NF-κB 
DNA-binding assay. (*p <0.05) 
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3.6.1.2 Garcinol inhibits the cisplatin-induced NF-κB activation in HNSCC 
cells. 
It is clearly evident from our earlier experiments that the therapeutic drug 
cisplatin was able to induce NF-κB activation in HNSCC. Also, we found that 
garcinol acted as a potent inhibitor of constitutive NF-κB activation in HNSCC 
cells. We next examined whether garcinol can also suppress the cisplatin-induced 
NF-κB activation. MDA686LN cells were exposed to various concentrations of 
garcinol and/or cisplatin as indicated for 12 h . The nuclear lysates were then 
prepared and subjected to western blot and NF-κB DNA-binding assays. Our 
results revealed that the cisplatin-induced NF-κB activation could also be 





Figure 3.6.1.2. Garcinol inhibits cisplatin-induced NF-κB activation in 
HNSCC cells. 
A. Nuclear lysates from solvent control, 15 μM garcinol, 25 μM cisplatin or their 
combination treated MDA686LN cells (1×106/mL) for 12 h were evaluated by 
western blot to assess the expression of p-p65 and p65 protein levels. Membrane 
was stripped and reprobed for lamin B1 to confirm equal loading. Representative 
blots from at least two independent experiments have been shown. 
B. MDA686LN cells (1×106/mL) were exposed to various concentrations of 
garcinol and/or cisplatin as i ndicated for 12 h , and the nuclear proteins were 
extracted and subjected to NF-κB DNA-binding assay. (*p <0.05) 
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3.6.1.3 Cisplatin induces the expression of various NF-κB-regulated gene 
products. 
We have previously demonstrated that cisplatin was able to induce 
significant activation of NF-κB in HNSCC cells. To investigate the possible 
modulatory effect of cisplatin on NF-κB regulated gene products, we examined 
the expression level of various proteins by w estern blot analysis. MDA686LN 
cells were harvested at different time points after cisplatin exposure, after which 
whole cell lysates were extracted and subjected to western blot analyzed. We 
observed the expression of MMP-9, ICAM-1 and COX-2 were substantially 







Figure 3.6.1.3. Cisplatin induces the expression of various NF-κB regulated 
gene products in HNSCC cells. 
After incubation of 25 µM garcinol for 0, 12, 24, 36, a nd 48 h, the expression 
levels of MMP-9, ICAM-1, and COX-2 in whole cell lysates were determined by 
western blot. β-actin as an internal control to verify equal loading of proteins was 
detected on the same membrane after stripping. Representative blots from at least 









3.6.1.4 Garcinol downregulates the expression of NF-κB regulated proteins 
in HNSCC cells. 
Given the inhibitory effect of garcinol on t he cisplatin-induced NF-κB 
activation demonstrated above, we next explored whether garcinol modulates the 
expression of NF-κB regulated proteins involved in HNSCC progression. 
MDA686LN cells were incubated with 15 μM garcinol, 5 μM cisplatin and their 
combination for 48 h; thereafter the whole cell lysates were extracted and 
subjected to western blot analysis. Our results revealed that garcinol treatment 
caused a substantial inhibition of both the constitutive and cisplatin-induced 






Figure 3.6.1.4. Garcinol downregulates the expression of NF-κB regulated 
proteins in HNSCC cells. 
Whole cell lysates from solvent control, 15 μM garcinol, 5 μM cisplatin or their 
combination treated MDA686LN cells (5×105/mL) for 48 h w ere evaluated by 
western blot to assess the expression of MMP-9, ICAM-1, and COX-2 protein 
levels. β-actin as an internal control to verify equal loading of proteins was 
detected on the same membrane after stripping. Representative blots from at least 






3.6.2 Garcinol potentiates the anti-cancer effects of cisplatin in HNSCC 
cells in vitro. 
3.6.2.1 Garcinol enhances the cytotoxic effects of cisplatin in HNSCC cells 
in vitro. 
Firstly, we examined whether garcinol treatment can augment the 
cytotoxic effect of cisplatin in HNSCC cells. CAL27 cells were treated with 15 
µM garcinol and different concentrations of cisplatin alone and/or in combination 
for 48 h, after which the cell viability were analyzed by MTT assay. Our results 
showed that the combination of garcinol with cisplatin could produce enhanced 
growth inhibitory effect than either agent used alone. The combination effects 





Figure 3.6.2.1. Garcinol augments the cytotoxic effect of cisplatin in HNSCC 
cells.  
A. CAL27 cells (5×105/mL) were exposed for 48 h to different concentrations of 
garcinol and cisplatin, and their combination as indicated above and then 
subjected to MTT assay to analyze the viability of tumor cells. Differences in cell 
growth after exposure to garcinol and cisplatin, alone and in combination, were 
determined with the one-way ANOVA test, * p <0.05. 
B. The synergy quantification of drug combination study was done using Chou-
Talalay method. The degree of synergy was assessed based on the combination 
index (CI), where CI values of >1.0 implies antagonism, 1.0 implies additive and 
<1.0 implies synergistic effect relationships. 
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3.6.2.2 Garcinol augments the apoptotic effects of cisplatin in HNSCC cells 
in vitro. 
We next investigated whether garcinol when employed at suboptimal 
concentration can potentiate the apoptotic effect of cisplatin in HNSCSS cells. 
CAL27, UMSSC1 and MDA686LN cells were treated with 15 µ M garcinol 
and/or 5 µM cisplatin for 48 h, and then analyzed by flow cytometry and western 
blot assays. It is clearly evident from our data that combination of garcinol and 
cisplatin produced significant apoptosis in all three cell lines, as evidenced by 
increase in sub-G1 population, while either agent alone only induced moderate 
apoptotic cell death. Furthermore, co-treatment of garcinol and cisplatin more 
potently activated caspase-3 and caused PARP cleavage, compared to single 
agents used individually. Overall, our results suggest that garcinol can indeed 




Figure 3.6.2.2. Garcinol augments the cisplatin-induced apoptosis in HNSCC 
cells. 
A. CAL27, UMSSC1, and MDA686LN cells (5×105/mL) were exposed to 15 µM 
garcinol and/or 5 µM cisplatin for 48 h, after which the cells were collected for 
fixation, PI staining, and then subjected to FACS analysis. Representative graphs 
of at least two independent experiments are shown. 
B. CAL27, UMSSC1 and MDA686LN cells (5×105/mL) were exposed to 15 µM 
garcinol and/or 5 µ M cisplatin for 48 h;  whole cell lysates were extracted and 
subjected to western blot using caspase-3 and PARP antibodies. β-actin as an 
internal control to verify equal loading of proteins was detected on the same 
membranes after stripping. Representative blots from at least two independent 
experiments have been shown. 
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3.6.3 Garcinol potentiates the anti-tumor effects of cisplatin in HNSCC 
xenograft mouse model. 
3.6.3.1 Garcinol enhances the inhibition of tumor growth induced by 
cisplatin in vivo. 
Based on the initial observation that garcinol has the capacity to enhance 
the apoptotic effects of cisplatin in HNSCC cell lines, we evaluated the in vivo 
therapeutic potential of garcinol and cisplatin either alone or in combination on 
the growth of HNSCC CAL27 xenografts in nude mouse. CAL27 cells were 
implanted subcutaneously into the right flank of athymic nude mice. The mice 
were then divided into four groups, one week post tumor inoculation when tumors 
reached 0.25 cm in diameter as p er the study protocol. The efficacy of the 
treatment was evaluated by t umor volume during the four week treatment. 
Significant decreases in the tumor volume in single agent treated group were 
observed from week 2 until the end of the experiment, and the combined 
treatment exerted more pronounced effect. The tumor volume in the combination 
of garcinol and cisplatin was significant lower than garcinol alone group (p < 0.05) 




Figure 3.6.3.1. Garcinol enhances the inhibition of tumor growth induced by 
cisplatin in vivo. 
A. Schematic representation of experimental protocol described in “Materials and 
Methods”. Group I was given 0.1% DMSO, group II was given garcinol (0.5 
mg/kg body weight), group III was given cisplatin (2 mg/kg body weight), and 
group IV was given garcinol (0.5 mg/kg) and cisplatin (2 mg/kg). 
B. The diameters of the tumor were measured twice per week, after which the 
tumor volume was calculated as: (longest diameter) × (shortest diameter) 2) × 0.5. 




3.6.3.2 Garcinol enhances the effects of cisplatin in abrogating Ki-67 and 
CD31 expression in HNSCC tumor tissues. 
As evident from our previous observations garcinol treatment alone 
suppressed the expression of proliferation marker Ki-67 and microvessel density 
marker CD31 in vivo, we next determined whether garcinol in combination with 
cisplatin could also exert similar effects. Tumor samples from garcinol and or 
cisplatin treated xenograft mice were evaluated by immunohistochemistry. We 
found that both garcinol and cisplatin downregulated the expression of Ki-67 in 
CAL27 tissue to a similar extent, and the two agents when used in combination 
together were most effective (p <0.01 versus vehicle; p < 0.01 versus cisplatin 
alone). Similarly, both agents significantly inhibited CD31 expression alone, and 
the maximum decrease was noted when the two drugs were used in combination 




Figure 3.6.3.2. Garcinol enhances the effect of cisplatin against tumor cell 
proliferative and angiogenesis biomarkers in HNSCC tumor tissues. 
A. Left panel, Tumor tissues obtained were subjected to immunohistochemistry 
using Ki-67 antibody. Representative image for each group is shown above. Right 
panel, quantification of Ki-67+ cells.  
B. Left panel, Tumor tissues obtained were subjected to immunohistochemistry 
using CD31 antibody. Representative image for each group is shown above. Right 
panel, quantification of CD31+ microvessel density.  
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3.6.3.3 Garcinol in combination with cisplatin downregulates the expression 
various oncogenic molecules involved in HNSCC progression.  
From our in vitro data, we found that garcinol suppressed both the 
constitutive and inducible NF-κB activation in HNSCC cell lines. Hence, we next 
evaluated the effects of garcinol and cisplatin on NF-κB levels and expression of 
various NF-κB-regulated gene products in HNSCC tumor tissues. Tumor tissue 
samples harvested from drug treated xenograft mice were analyzed by western 
blot and immunohistochemistry analysis. Western blot analysis of nuclear extract 
of tumor tissue showed that garcinol either alone or in combination with cisplatin 
was effective to suppress the constitutive NF-κB (p65) expression in HNSCC 
tumor tissues. The results of western blot analysis also clearly showed that the 
combination treatment of garcinol and cisplatin also substantially downregulated 
the expression of COX-2, VEGF, and MMP-9 proteins. The IHC analysis results 







Figure 3.6.3.3. Garcinol in combination with cisplatin suppresses NF-κB 
activation and the expression of NF-κB-regulated gene products in HNSCC 
tumor tissues. 
A. Proteins extracted from the all four treatment groups were subjected to western 
blot using various antibodies as indicated. β-actin as an internal control to verify 
equal loading of proteins was detected on the same membrane after stripping. 
Samples from three mice in each group were analyzed and representative data are 
shown. 
B. Tumor tissues obtained were subjected to immunohistochemistry using 
antibodies against NF-κB, COX-2, VEGF, and MMP-9 proteins. Representative 





4.1 General discussion 
Despite the recent medical advances in the development of sophisticated 
systemic therapy, the five-year survival rate of advanced HNSCC remains low 
with minimal improvement over the past decades (132). Multidisciplinary 
approaches involving surgical excision, radiation therapy and chemotherapy are 
applied for the treatment of HNSCC, but frequently failed due to chemoresistance, 
tumor recurrences and distant metastases in locoregionally advanced disease (8). 
Platinum compounds such as cisplatin and carboplatin are used as the first-line 
chemotherapy for the treatment of HNSCC, although many other agents have also 
been extensively studied (138, 139). A meta-analysis of a panel of clinical trials 
has revealed that platinum containing regimens exhibit higher response rates than 
non-platinum therapies (266). Unfortunately, only 20 t o 40% of the patients 
experience complete response to platinating agents, mainly because of the 
intrinsic or acquired resistance to chemotherapy (150). High dose of platinating 
agents which are required for significant antitumor effect lead to frequent and 
severe side effects such as nausea, vomiting, mucositis, neurotoxicity, and renal 
dysfunction that compromise quality of life of the patients (148, 267) (Table 3). 
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For the above reasons, novel agents with lower toxicity which can enhance the 
effects of current chemotherapeutic drugs and overcome the chemoresistance are 
in great need. 
Natural products for ancient medical uses such as t raditional Chinese 
medicine and Ayurveda practiced in India are gaining increasing patronage for the 
treatment of cancer in recent years (169, 268). Garcinol, a poly-isoprenylated 
benzophenol, is one such compound extracted from the dried rind of the fruit of 
Garcinia indica tree which is used as a traditional folk medicine for the treatment 
of inflammatory conditions as diverse as rheumatism, edema, ulcer and infectious 
diseases (173). Garcinol has gained much attention in the field of cancer research 
in recent years, and several reports have demonstrated its significant anti-





4.1.1 Garcinol inhibits cell viability and induces programmed cell death in 
HNSCC cells. 
It is well documented that most anticancer agents induce cell cycle arrest 
and/ or apoptosis (229, 269). As described earlier, garcinol has been reported to 
inhibit cell proliferation and induce apoptosis in a various types of tumor cells but 
not in HNSCC cell lines previously. Using MTT assay, we confirmed the ability 
of garcinol to significantly suppress the viability of human HNSCC cell lines in a 
time- and dose- dependent manner. Interestingly, garcinol exhibited minimal 
cytotoxic effects against non-cancerous cells normal liver (LO2) and breast 
epithelial (MCF10A), cell lines, thereby indicating its specificity towards tumor 
cells (data not shown). Prior studies have also reported that garcinol exerts potent 
growth inhibitory effects on c olon cancer (HT-29 and HCT-116) and breast 
cancer cell lines (MDA-MB-231 and MCF-7), but much less effective in 
inhibiting the growth of normal immortalized intestinal cells (IEC-6 and INT-407) 
and normal breast epithelial cell line (MCF-10A) (198, 270).  
The inhibition of HNSCC cell viability by garcinol could be attributed to the 
ability of garcinol to suppress the cell proliferation, induce apoptosis, or a 
combination of the two. The most accurate method to measure cell proliferation is 
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by directly measuring DNA synthesis. Conventionally, the detection was achieved 
by incorporation of radioactive deoxynucleoside such as [3H] thymidine or 
thymidine analogue bromo-deoxyuridine (BrdU) (271, 272). The use of EdU as a 
novel alternative to the BrdU assay allows faster, more efficient detection by a 
fluorescent azide through direct conjugation to the thymidine analogue (271). Our 
data confirmed the ability of garcinol to inhibit the HNSCC cell proliferation in a 
time- and dose-dependent manner.  
To investigate whether the garcinol-induced cell death was due to the 
apoptosis, multiple approaches have been employed. We observed that garcinol 
caused substantial increased accumulation of HNSCC cells in sub-G1 population, 
induced DNA fragmentation and increased the percentage of annexin V-positive 
cells, providing solid evidences that cell death induced by garcinol is apoptotic in 
nature. The apoptosis induced by garcinol was caspase-3 dependent as evidenced 
by the elevated level of active (cleaved) caspase-3. Moreover, we noticed that the 
garcinol-induced apoptosis involved both caspase-8 mediated extrinsic and 
caspase-9 mediated intrinsic apoptotic pathways. Our findings are in accordance 
with the observations that garcinol-induced substantial activation of caspase-8 and 
caspase-9 in diverse pancreatic, colon and liver cancer cell lines (199, 231, 233). 
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4.1.2 Garcinol modulates the expression of cell cycle regulator proteins. 
D type cyclins form complex with function as regulatory subunits of CDK 
that control the transition from G1 to S phase of the cell cycle (273, 274). 
Dysregulation of cyclin D1 alters cell cycle progression, results in uncontrolled 
cell proliferation as the hallmark of cancer (275). Abnormal expression of cyclin 
D1 has been implicated in the pathogenesis of several types of cancers including 
HNSCC (276). It is evident that garcinol suppressed the expression of cyclin D1 
in HNSCC cells in a time-dependent manner. Cyclin E is a late G1 cyclin, which, 
along with its catalytic subunit CDK2, phosphorylates the CDK inhibitor p27Kip1 
and bring it to destruction in proteasomes (273). The high levels of cyclin E and 
low levels of p27 a re indicative of reduced long-term survival and increased 
mortality in various forms of cancer (273, 277). Similarly, we also found that 
garcinol downregulated the expression of cyclin E, and increased the level of p27 
protein in a time-dependent manner. The inhibition of cyclin D1 and cyclin E 
expression, together with the upregulation of p27 may account for garcinol’s 




4.1.3 Garcinol alters the balance between pro-apoptotic and anti-apoptotic 
proteins to induce apoptosis. 
The balance between pro-apoptotic and anti-apoptotic proteins of Bcl-2 
family determines the cell fate whether they undergo apoptosis (278, 279). We 
found that garcinol downregulated the protein and mRNA expression of various 
anti-apoptotic molecules, namely Bcl-2, Bcl-xL and Mcl-1, in concordance with 
several prior studies (217, 231-233). Most of the above studies have also observed 
that garcinol could increase the expression of anti-apoptotic protein Bax. On the 
contrary, our results revealed that the expression levels of Bax and Bak remained 
largely unaltered upon garcinol treatment, in accordance with the experimental 
findings by Liao and coworkers (217). Inhibitor of apoptosis protein (IAP) family 
is another group of important negative regulators of apoptosis (280). For example, 
survivin and XIAP can bind the effector caspase-3, -7 and -9 and inhibit the 
caspase activity (280, 281), whereas both of the two isoforms of c-FLIP block 
caspase-8 activation (282). Interestingly, we found that garcinol downregulated 
these above mentioned direct inhibitors of caspases; and together with the 




4.1.4 Garcinol suppresses the expression of proteins involved in 
angiogenesis. 
Tumor-associated neovasculature, generated by the process of 
angiogenesis develops during tumorogenesis to facilitate tumor acquiring 
nutrients and oxygen and disposing metabolic wastes (4). This process is initiated 
by ‘angiogenic switch’ in which the balance between pro-angiogenic and anti-
angiogenic factors is tipped towards angiogenesis (283). HNSCC cells have been 
found to express and secret pro-angiogenic factors such as the major contributor 
to angiogenesis VEGF, and various growth factors (e.g. PDGF) and cytokines (e.g. 
IL-8), which are usually associated with poor prognosis (253, 284). We examined 
the effects of garcinol on VEGF in HNSCC cell lines and observed a decreased 
expression of VEGF at both the protein and mRNA level. Interestingly, the 
decrease in this angiogenic growth factor, in turn, correlated with a significant 
decrease in microvessel density biomarker CD31 as observed in our in vivo study. 
Taken together, these findings suggest a potential ability of garcinol to inhibit 




4.1.5 Garcinol exerts anti-migratory and anti-invasive effects against 
HNSCC cells. 
Tumor cells are known to secrete MMPs, which are thought to degrade 
extracellular matrix (ECM) and facilitate tumor cell invasion in tissues, that 
MMP-9 and MMP-2 is well established to play the most important role in the 
process of epithelial-mesenchymal transition (EMT) (285). The cell adhesion 
molecule, ICAM-1 has been implicated in various stages of tumor progression 
and metastasis (286, 287). Functional CXC chemokine receptor 4 (CXCR4) is 
usually preferentially expressed in high level in certain metastatic HNSCC tissues 
and promotes the establishment of lymph node metastasis (288-290). In xenograft 
mouse model, CXCR4 antagonist blocks both growth of primary tumor and 
metastasis of HNSCC (291). Moreover, the sole ligand of CXCR4, chemokine 
CXCL12, has been found to induce CXCR4 mediated MMP-9 secretion in 
HNSCC (292). Interestingly, our experimental findings showed that CXCL12 
induced a significant migration and invasion of HNSCC cells. We observed that 
garcinol effectively attenuated the process of CXCL12-induced migration and 
invasion, that are in agreement with the observations found in colon, breast cancer, 
prostate and pancreatic cancer cell lines (199, 201, 204, 217). The significant 
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reduction of tumor cell migration and invasion directly correlated with the 
garcinol-induced downregulation of MMP-9, MMP-2, ICAM-1 and CXCR4 
proteins. Overall, our data clearly established the anti-invasive potential of 















4.2 Garcinol inhibits the STAT3 signaling cascade in HNSCC cells. 
The activation STAT3 signaling in cancer cells regulates the expression of 
numerous genes to supports tumor cell proliferation, survival, angiogenesis and 
metastasis (70, 293). As garcinol treatment in HNSCC cells resulted in 
suppression of cell growth, induction of apoptosis, along with the downregulation 
of various gene products ; we also investigate whether garcinol exhibit its anti-
neoplastic effects by modulating STAT3 signaling pathway in HNSCC cells. Our 
findings showed that garcinol indeed suppressed both constitutive and IL-6 
induced STAT3 phosphorylation at tyrosine 705 residue in a variety of HNSCC 
cells. In addition to canonical tyrosine phosphorylation, STAT3 is also 
phosphorylated at serine residue regulating the transcriptional activity. We 
conducted western blot using serine phosphorylation specific antibody to explore 
the status of serine phosphorylation in HNSCC cells upon garcinol treatment. We 
observed that garcinol did not alter the level of serine phosphorylation, indicating 
that garcinol specifically inhibited tyrosine phosphorylation of STAT3. Next, we 
noticed that the garcinol-induced inhibition of STAT3 occurs in parallel with the 
suppression of the upstream kinases (Src, JAK1, and JAK2). Prior reports have 
revealed that Src and JAK2 act cooperatively to regulate the constitutive 
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activation of STAT3 (261, 294). Our data suggested that garcinol may block the 
cooperation of Src and JAK kinases regulating STAT3 phosphorylation. Tyrosine 
phosphatases negatively regulate STAT3 activation by dephosphorylating the 
signaling molecules in the STAT3 pathway (73, 295). Many physiological 
inhibitors of STAT3 and natural compounds have been reported to suppress 
JAK/STAT signaling by upregulating the expression of PTPs, or promoting the 
phosphatase activities (296-298). Thus, we also explored the possible 
involvement of tyrosine phosphatases in garcinol-induced inhibition of STAT3 
activation. However, treatment with garcinol did not affect the expression and/or 
phosphorylation of the important PTPs in HNSCC cells, suggesting that this 
benzophenone inhibitory effect on STAT3 signaling cascade is not mediated via 
induction of phosphatases. Also, whether garcinol affects other STAT3 inhibitors 
such as protein inhibitors of activated STAT3 (PIAS3) and suppressor of cytokine 
signaling (SOCS) in HNSCC cells needs further investigation. STAT3 monomers 
form dimers upon t yrosine phosphorylation, and then translocate to the nucleus 
where they bind to specific DNA to activate transcription (70). We noted that 
garcinol negatively regulated STAT3 signaling cascade at multiple steps as 
experiments as STAT3 nuclear translocation, DNA-binding ability and IL-6/EGF 
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induced reporter activity of STAT3 were significantly abrogated upon garcinol 

















4.3 Garcinol suppresses NF-κB signaling pathway in HNSCC cells. 
It has been reported previously that aberrant NF-κB signaling contributes to 
different stages in HNSCC initiation and progression (123-125). And our 
experimental findings have demonstrated that garcinol inhibited cell viability, 
induced apoptosis, and abrogated processes of migration and invasion, in parallel 
with downregulating the expression of various oncogenic proteins involved in cell 
cycle, survival, invasion, and angiogenesis. We hypothesized that inhibition of 
NF-κB signaling cascade by may at least in part contribute to its observed anti-
neoplastic effects in HNSCC cells. We first found that NF-κB is constitutively 
active in HNSCC cells, but the exact reason, why it is  persistently active is still 
not clear. Our results showed that garcinol suppressed phosphorylation and 
degradation of the constitutive IκBα, thereby prevented the nuclear translocation 
of NF-κB p65 subunit as evidenced by decreased p65 level in the nucleus. 
Optimal NF-κB activation requires phosphorylation on functional domains of NF-
κB proteins, for example, phosphorylation of p65 a t Ser536 enhance p65 
transactivation potential in most cases (299). We also noticed that garcinol 
suppressed p65 phosphorylation at Ser 536 residue in a time-dependent manner in 
HNSCC cells. Consistently, by E LISA-based Trans AM™ NF-κB assay, we 
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found that treatment of HNSCC cells with garcinol inhibited DNA binding ability 
of NF-κB. The inhibition of IKK activation by garcinol suggests that it abolished 
NF-κB activation in HNSCC cells indirectly through the suppression of IKK 
phosphorylation. Several kinases, such as Akt, mitogen-activated protein 
kinase/ERK kinase kinase 1 (MEKK1), MEKK3, protein kinase C (PKC), GSK-
3β, phosphoinositide-dependent protein kinase-1 (PDK1), and TAK1, (300), have 
been reported to function upstream of IKK. We also reported for the first time that 
garcinol could inhibit the constitutive TAK1 activation in HNSCC cells. 
Moreover, a prior study indicates that the constitutive activation of NF-κB in 
HNSCC cells is mediated through the TRADD-TRAF2-RIP-TAK1-IKK pathway 
(301), and our results clearly indicate that garcinol can indeed abrogate TAK1-
mediated IKK activation. 
Previous studies have also indicated that several chemotherapeutic agents 
including platinum compounds induce the activation of NF-κB signaling in 
protection from genotoxic stress, which lead to the drug resistance in tumor cells 
(115, 264, 302). For example, cisplatin has been shown to significantly induce 
NF-κB promoter activity, accompanied with the increase in nuclear p65 and p50 
protein levels in HNSCC cell lines (303). However, the role of NF-κB in 
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chemoresistance remains controversial (304). Interestingly, we found that 
cisplatin can substantially increase nuclear p65 expression and phosphorylation 
level as well as NF-κB DNA binding activity in HNSCC cells, and such cisplatin-
induced NF-κB activation could also be effectively suppressed by garcinol. A 
recent report has suggested that NF-κB can also mediate cisplatin-induced 
resistance through histone modifications in HNSCC cells (265), and thus 
inducible NF-κB inhibitory effects of garcinol may be mediated through its 
previously documented potent histone acetyltransferases blocking effects as 
observed in other tumor cells (188). Our results are also in part agreement with 
another study in which curcumin was also found to enhance the effect of cisplatin 
in suppression of HNSCC via inhibition of IKKβ protein of the NF-κB pathway 
(305). We further observed that cisplatin also substantially induced the expression 
of the oncogenic MMP-9, ICAM-1 and COX-2 proteins, and garcinol treatment 
was able to suppress both constitutive and cisplatin-induced expression of these 
diverse NF-κB-regulated gene products involved in HNSCC progression. 
Different modes of functional interaction between STAT3 and NF-κB have 
been discovered in tumors. One interesting study had shown that STAT3 could 
prolong NF-κB nuclear retention through acetyltransferase p300-mediated RelA 
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acetylation, thereby interfering with NF-κB nuclear export (306). Thus, it is 
possible that suppression of STAT3 activation may mediate the inhibition of NF-
κB activation by garcinol. Also, the constitutive activation of NF-κB in HNSCC 
leads to the production and secretion of cytokines such as IL-6 in an 
autocrine/paracrine manner, which causes the consequent activation of STAT3 
signaling (307). Importantly, STAT3 and NF-κB control both distinct and 
overlapping groups of genes involved in cell proliferation, survival, angiogenesis 
and invasion (308, 309). Our work has demonstrated that garcinol inhibited both 
constitutive and inducible STAT3/NF-κB activation and downregulated various 
STAT3/NF-κB-regulated genes, as one of the mechanisms behind the 
observations of garcinol-induced apoptosis, inhibition of cell viability, and the 
abrogation of tumor cell invasion and migration in HNSCC cells. Although 
previous studies have shown that garcinol can modulate AKT survival signaling 
cascade in colorectal cancer cells (217), our study is also the first report to 
examine the effect of garcinol on Akt/mTOR/S6K1 signaling axis in HNSCC 
cells. We found that garcinol inhibited the phosphorylation of Akt, mTOR, and 
S6K1 in a time-dependent manner in HNSCC cells, which further indicates the 
possibility that garcinol could interfere with the mTOR-rictor complex that 
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phosphorylates Akt at Ser473. Akt is also reported to regulate the master 
transcription factor NF-kB through the phosphorylation of p65 t o enhance the 
transcriptional activity of NF-kB (310). Furthermore, Akt is also involved in the 
regulation of IL-6 induced STAT3 signaling pathway (261). Thus, it is possible 
that the inhibition of AKT/mTOR/S6K pathways may contribute to STAT3/NF-












4.4  Garcinol potentiates the apoptosis induced by cisplatin in HNSCC cells. 
There are only few published reports in which garcinol have been used in 
combination with existing neoplastic agents. Garcinol has been shown to 
potentiate the apoptotic effects of natural ligand TRAIL in colon cancer (231), 
and natural compound curcumin in pancreatic cancer (237). And only one study 
by Parasramka’s group has demonstrated that garcinol significantly sensitized 
pancreatic cancer cells to the first-line pancreatic cancer drug, gemcitabine (221). 
However, there are no prior reports investigating the potential of garcinol as 
chemosensitizing agent against HNSCC cell lines. Our study showed for the first 
time that garcinol when used at sub-optimal concentrations significantly enhanced 
the cytotoxic and apoptotic effects of the chemotherapeutic drug cisplatin against 
a number of HNSCC cell lines. Also, cisplatin was been found to significantly 
induce NF-κB activation as evidenced by the increased nuclear p65 protein and 
phosphorylation level, and enhanced NF-κB DNA binding activity; and both the 
constitutive and cisplatin-induced NF-κB activation could be suppressed by 
garcinol. Therefore, it is conceivable that garcinol attenuated NF-κB-mediated 
drug resistance that may lead to the observed enhanced apoptotic effect. Also, the 
pleiotropic nature of garcinol with its ability to modulate multiple signaling 
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pathways including STAT3 and Akt cascades as reported above, may contribute 

















4.5 Anti-tumor effects of garcinol in HNSCC xenograft mouse model 
Whether the in vitro observations with garcinol have any relevance to the in 
vivo context was also investigated. 
4.5.1 Pharmacokinetic properties of garcinol 
In order to examine the efficacy of garcinol in a xenograft mouse model, a 
pharmacokinetic study of garcinol was conducted to define suitable doses for 
treatment of mice in pharmacodynamics study. Two doses of garcinol (0.5 and 2 
mg/kg) were used for evaluation of pharmacokinetic property of garcinol through 
intraperitoneal administration. The pharmacokinetic results indicated that garcinol 
showed a sufficient systemic exposure and good dose proportionality which is an 
important property for garcinol in its translational development from animal to 
human subjects. The pharmacokinetic results suggested that 0.5 and 2 mg/kg of 





4.5.2 Garcinol inhibits the growth of HNSCC xenograft tumor. 
Our results indeed indicate for the first time that garcinol significantly 
inhibited HNSCC growth in a nude mouse model without exhibiting any 
significant toxicity, and downregulated the expression of proliferation marker Ki-
67, and microvessel density index CD31. To the best of our knowledge, no prior 
studies with garcinol in xenograft HNSCC models have been reported previously, 
and thus our novel findings suggest that garcinol may have a tremendous potential 
for the treatment of HNSCC. Interestingly, garcinol has been tested before in 
chemically-induced HNSCC models, and presented chemopreventive effects 
against 4-NQO-induced tongue cancer in rats (245) and DMBA-induced oral 
cancer in hamster cheek pouch (211); however, its activity against HNSCC 






4.5.3 Garcinol potentiates the inhibition of tumor growth induced by 
cisplatin in nude mice. 
Up to date, there is only one in vivo combination study published recently, 
revealing that garcinol enhances the effect of targeted therapy (anti-ERBB2 
antibody) against breast cancer in a syngeneic tumor model (190). However, the 
effects of garcinol in combination with anticancer therapies in HNSCC mouse 
models have never been evaluated before. When examined in xenograft mouse 
model, garcinol or cisplatin alone was found to inhibit the tumor growth 
effectively, and the combination of these two agents markedly augmented the 
effect to a greater extent. This observation was in parallel with the enhanced 
suppression of Ki-67 and CD31 observed in the tumor tissues with the drug 
combination, thereby indicating that garcinol enhanced the inhibition of 
proliferation and angiogenesis in combination with cisplatin. This is the first study 
to systematically analyze the effects of garcinol in combination with an approved 




4.5.4 Garcinol inhibits the expression of STAT3 and NF-κB in HNSCC 
tumor tissues. 
We also investigated whether the effects of garcinol induced tumor growth 
retardation in mice were mediated by the abrogation of both STAT3 and NF-κB 
activation cascades. As shown by I HC analysis, garcinol downregulated the 
expression of activated STAT3 and NF-κB expression in the garcinol treated 
groups as compared with the control group. These experimental findings are in 
agreement with the studies showing that the anti-tumor action of garcinol in 
xenograft breast cancer and hepatocellular carcinoma models is mediated through 
inhibition of STAT3 signaling (204, 311). However, the effects of garcinol on 
NF-κB activation cascade are not well characterized in vivo models. Our studies 
demonstrate for the first time that garcinol in combination with cisplatin further 





4.5.5 Garcinol in combination with cisplatin downregulates the expression 
of proteins involved in HNSCC progression in vivo. 
In order to further validate the suppressive effects of garcinol on NF-κB 
signaling observed in HNSCC cell lines, we performed western blot and IHC 
analysis to examine whether garcinol-cisplatin combination modulates NF-κB-
regulated gene products involved in HNSCC progression in a xenograft mouse 
model. The analysis on human HNSCC tumor tissues demonstrated that garcinol 
in combination with cisplatin significantly suppressed the overexpression of 
critical oncogenic molecules involved in proliferation (cyclin D1, COX-2), 
survival (Bcl-xL, survivin), angiogenesis (VEGF) and invasion (MMP-9, ICAM-
1), and such downregulation was more impressive than observed with either 
garcinol or cisplatin alone. Overall, our findings clearly demonstrate that garcinol 
significantly suppresses the activation of NF-κB signaling cascade thereby 
inhibiting the expression of various oncogenic biomarkers of proliferation, 






In summary, our studies demonstrated that the garcinol, an active component 
of Garcinia indica, suppressed HNSCC cell viability, induced programmed cell 
death and inhibited the processes of cellular migration and invasion; the observed 
anti-cancer effects of garcinol are correlated with the donwregulation of various 
gene products involved in diverse aspects of HNSCC growth, survival, 
angiogenesis, invasion, and metastasis. We then identified STAT3 and NF-κB as 
the important signaling cascades being modulated upon garcinol treatment in 
HNSCC cells. Garcinol suppressed both constitutive and IL-6-induced STAT3 
activation in parallel with the suppression of the upstream kinases (c-Src, JAK1, 
and JAK2) in HNSCC cells, while the polyisoprenylated benzophenone inhibited 
NF-κB signaling through the modulation of TAK1-mediated IKK activation. The 
modulatory effect of garcinol on these pathways was further verified by t he 
downregulation of p-STAT3 and p65 expression in tumor samples from garcinol 
treated xenograft mice. Thereafter, we carried out experiments to evaluate the 
potential of garcinol in sensitizing the HNSCC to cisplatin treatment both in 
HNSCC cell lines and in xenograft mouse model. Interestingly, we observed that 
cisplatin induced NF-κB activation and upregulated the expression of various NF-
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κB-regulated gene products, implying a plausible mechanism for the frequently 
occurred resistance to this HNSCC first-line chemotherapeutic agent. Also, 
garcinol was able to suppress the cisplatin-induced NF-κB activation, 
downregulate the expression of various NF-κB-regulated proteins, and potentiate 
the cisplatin-induced apoptosis in HNSCC cells. Furthermore, our in vivo study 
showed that the combination treatment of garcinol and cisplatin significantly 
reduced the growth of HNSCC xenograft tumors in nude mice. Further analysis of 
tumor tissues demonstrated that garcinol inhibited NF-κB, as well as the target 
gene products involved in proliferation (cyclin D1, COX-2), survival (Bcl-xL, 
survivin), angiogenesis (VEGF) and invasion (MMP-9, ICAM-1); moreover, it 
exerted significant enhanced effects when combined with cisplatin. Overall, our 
results clearly validate the anti-cancer effects of garcinol in HNSCC are mediated 
through suppression of multiple pro-inflammatory signaling cascades; the 
experimental evidences of garcinol’s capability to potentiate the effects of 
cisplatin provide a solid rationale for pursuing the application of garcinol further 




Figure 5.1. Schematic diagram representing the molecular mechanism(s) of 











Table 1: Selected ongoing clinical trials in HNSCC patients 
Abbreviations: TKI, tyrosine kinase inhibitor; mAb, monoclonal antibody 
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Table 3: Toxicities associated with cisplatin-based chemotharepy in HNSCC 
patients
Abbreviations: CT, chemotherapy; RT, radiotherapy; CRT, concurrent 
chemoradiotherapy; P, cisplatin; PF, cisplatin and fluorouracil; PT, cisplatin and 




6 FUTURE DIRECTIONS 
A recent report from our laboratory has utilized a computational modeling to 
explore the direct molecular targets of garcinol and showed that garcinol could 
directly bind to the SH2 domain of STAT3 and suppress its dimerization in vitro 
(311). Elucidating the detailed molecular mechanism(s) by which garcinol can 
modulate multiple oncogenic signaling pathways will provide deeper 
understanding of its mechanisms of action against various tumor cells. Although 
garcinol has been reported to exhibit chemopreventive and tumor inhibitory 
effects in chemically-induced HNSCC models or subcutaneous xenografts, the 
efficacy of the drug in metastatic disease in vivo has not been studied yet. A well 
established cell line-derived or patient-derived tumor orthotopic xenograft model 
could be established to evaluate the anti-metastatic potential of garcinol in vivo 
against HNSCC. Diverse doses or concentrations of garcinol have been applied in 
various animal models, however, garcinol has not been so far tested in humans as 
an anticancer agent, and hence the clinically relevant doses are not clear as of yet. 
Thus, systematic study of the toxicology on garcinol should be addressed to 
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